Mode of action of non-genotoxic carcinogens by Pichlbauer, Melanie
  
 
 
 
 
 
 
 
 
 
MASTERARBEIT 
Titel der Masterarbeit 
„Mode of action of non-genotoxic carcinogens“ 
 
Verfasserin 
Melanie Pichlbauer (Bakk. techn.) 
angestrebter akademischer Grad 
Master of Science (MSc) 
Wien, 2012  
Studienkennzahl lt. Studienblatt: A 066 830 
Studienrichtung lt. Studienblatt: Masterstudium Molekulare Mikrobiologie und Immunbiologie 
Betreuerin / Betreuer: Univ.-Prof. Mag. Dr. Pavel Kovarik 
 
 
  
 
1 
 
 
  
  
 
2 
 
Externe Betreuung durch 
Frau Ao.-Univ.-Prof. Dr. Bettina Grasl-Kraupp 
 
Institut für Krebsforschung 
Forschungseinheit für Chemikaliensicherheit und Krebsprävention 
Medizinische Universität Wien  
 
  
  
 
3 
 
 
 
  
 
4 
 
Table of contents 
 
1. Introduction ........................................................................................................ 8 
1.1 The liver: A multitasking organ ............................................................................. 8 
1.1.1 Liver structure  and its function ......................................................................... 8 
1.1.2 Liver cell types and “the fantastic four” ............................................................. 8 
1.2 Hepatocarcinogenesis ........................................................................................10 
1.2.1 Carcinogenesis ...............................................................................................10 
1.2.2 Hepatocellular carcinoma (HCC) .....................................................................11 
1.2.3 Cirrhosis ..........................................................................................................11 
1.3 Inflammation and cancer .....................................................................................12 
1.3.1 The link between inflammation and liver cancer ..............................................12 
1.3.2 Tumor necrosis factor-alpha (TNFα) ................................................................13 
1.3.3 Interleukin 6 (IL-6) ...........................................................................................13 
1.3.4 Cyclooxygenase 2 (COX-2) .............................................................................14 
1.3.5 Inducible nitric-oxide synthase (iNOS) .............................................................14 
1.4 The role of mitogen-activated protein kinases (MAPKs) in HCC .........................15 
1.4.1 Function of MAPKs .........................................................................................15 
1.4.2 Activation of the MAPK signalling pathway ......................................................15 
1.4.3 The ERK pathway ...........................................................................................15 
1.4.4 The role of ERK pathway in HCC ....................................................................16 
1.5 Carcinogens .......................................................................................................16 
1.5.1 Genotoxic carcinogens (GC) versus non-genotoxic carcinogens (NGC)..........16 
1.5.2 Characteristics of NGC ....................................................................................16 
1.5.3 Phenobarbital (PB) ..........................................................................................17 
1.5.4 Cyproterone acetate (CPA) .............................................................................17 
1.5.5 Wyeth-14,643 (WY) .........................................................................................18 
1.6 The cytochrome P450 superfamily (CYP) ...........................................................19 
1.6.1 NGC-induced CYP enzymes ...........................................................................19 
1.7 Nuclear receptors (NR) .......................................................................................20 
1.7.1 Class I receptors .............................................................................................20 
1.7.2 Class II receptors ............................................................................................21 
 
2. Aims .................................................................................................................. 23 
 
  
 
5 
 
3. Materials and Methods .................................................................................... 25 
3.1 Reagents ............................................................................................................25 
3.2 Buffers and Solutions ..........................................................................................26 
3.3 Media ..................................................................................................................28 
3.3.1 Media for hepatocytes .....................................................................................28 
3.3.2 Media for non-parenchymal cells .....................................................................28 
3.3.3 Media for HepG2 cell line ................................................................................28 
3.4 Animals and treatment ........................................................................................29 
3.5 Liver perfusion ....................................................................................................30 
3.6 Cell separation and cell culture ...........................................................................30 
3.6.1 Isolation and culture of primary hepatocytes ...................................................30 
3.6.2 Isolation and culture of non-parenchymal cells ................................................31 
3.6.3 Culture of the HepG2 cell line ..........................................................................31 
3.6.4 Determination of cell number and vitality .........................................................32 
3.7 In vitro treatment of cells .....................................................................................32 
3.7.1 Treatment of cells with specific reagents .........................................................32 
3.7.2 Treatment of cells with supernatants ...............................................................32 
3.8 Methods on RNA level ........................................................................................33 
3.8.1 RNA isolation from cells ..................................................................................33 
3.8.2 RNA isolation from tissue ................................................................................34 
3.8.3 Reverse Transcription-PCR (RT-PCR) ............................................................34 
3.8.4 Polymerase Chain Reaction (PCR) .................................................................35 
3.8.5 Agarose gel electrophoresis ............................................................................36 
3.8.6 Quantitative real time-PCR (qrt-PCR) ..............................................................36 
3.8.7 Microarray analysis .........................................................................................38 
3.9 Methods on DNA-level ........................................................................................39 
3.9.1 Autoradiography ..............................................................................................39 
3.10 Methods on protein level .................................................................................39 
3.10.1 Isolation of proteins from cells .........................................................................39 
3.10.2 Isolation of proteins from tissue .......................................................................39 
3.10.3 Determination of protein concentrations ..........................................................40 
3.10.4 Western blot ....................................................................................................40 
3.10.5 Enzyme-linked immunosorbent assay (ELISA) ................................................41 
 
  
  
 
6 
 
4. Results .............................................................................................................. 42 
4.1 Gene expression pattern of CYP in liver cell types ..............................................42 
4.1.1 Basal mRNA level of CYP in untreated primary liver cells ...............................42 
4.1.2 mRNA level of CYP in treated primary liver cells .............................................43 
4.2 Gene expression pattern of NR ...........................................................................45 
4.2.1 Basal mRNA level of NR in untreated primary liver cell types ..........................45 
4.2.2 mRNA level of specific NR in treated primary liver cell types ...........................47 
4.2.3 qrt-PCR analyses of NR in treated and untreated primary liver cell types ........49 
4.2.4 Specific inhibitors for PXR and CAR ................................................................51 
4.3 Gene expression pattern of specific pro-inflammatory factors .............................53 
4.3.1 Supernatant effects of isolated liver cell types .................................................55 
4.4 Analysis of TNFα as pro-inflammatory factor ......................................................57 
4.4.1 Treatment of primary liver cells with recombinant TNFα ..................................57 
4.4.2 TNFα release ..................................................................................................58 
4.5 DNA Chip analysis of the 24 hours CPA in vivo treatment ..................................59 
4.5.1 Overview of regulated genes ...........................................................................59 
4.5.2 Influence of CPA in vivo treatment on CYP .....................................................59 
4.5.3 Influence of in vivo treatment with CPA on the expression of pro-inflammatory 
genes  ........................................................................................................................60 
4.5.4 Influence of treatment with CPA on the ERK pathway .....................................62 
4.6 The MAPK/ERK pathway on protein level ...........................................................64 
4.6.1 Effect of PB treatment on ERK phosphorylation ..............................................65 
4.6.2 Effect of CPA treatment on ERK phosphorylation ............................................66 
 
5. Discussion ........................................................................................................ 68 
5.1.1 Are NPC direct targets of NGC effects? ..........................................................68 
5.1.2 Do NPC express NR? .....................................................................................69 
5.1.3 What are the effects of in vivo treatment with CPA on the whole transcriptome? 
  ........................................................................................................................70 
5.1.4 Are their direct or indirect effects of NGC on NPC? .........................................71 
5.1.5 Which pathway is affected by NGC? ...............................................................72 
5.1.6 Conclusion and perspectives ...........................................................................73 
 
6. Abstract ............................................................................................................ 74 
 
7. Zusammenfassung .......................................................................................... 76 
  
 
7 
 
 
8. References ........................................................................................................ 78 
 
9. Appendix ........................................................................................................... 84 
9.1 List of Tables ......................................................................................................84 
9.2 List of Figures .....................................................................................................85 
9.3 List of abbreviations ............................................................................................86 
9.4 Curriculum vitae ..................................................................................................89 
 
DANKSAGUNG 
  
  
 
8 
 
1. Introduction 
For a better understanding of the mode of action of non-genotoxic carcinogens (NGC) in 
hepatocarcinogenesis, the following parts describe the unique functions and characteristics 
of the liver and its various cell types. 
 
1.1 The liver: A multitasking organ 
1.1.1 Liver structure and its function 
The liver is a heterogeneous organ, being composed of five tissue systems: (1) the vascular 
system, (2) hepatocytes (HC) and hepatic lobule, (3) hepatic sinusoidal cells, (4) biliary 
system and (5) stroma. The vascular system comprises mainly of the portal vein and the 
hepatic artery which supply blood to the liver. The general functions of the liver involve the 
metabolism of amino acids and proteins, carbohydrates, bile acids, cholesterol, lipids and 
vitamins. Additionally, it is the major organ for biotransformation and defence against foreign 
macromolecules and xenobiotics. (Malarkey, et al., 2005; Hiromi, et al., 2009) 
 
1.1.2 Liver cell types and “the fantastic four” 
Many different cell types are present in the liver. Generally, hepatocytes are denoted as 
parenchymal cells. Endothelial cells (EC), Kupffer cells (KC), hepatic stellate cells (SC), 
natural killer (NK) cells, hepatic dendritic cells (DC) and NKT cells are summarized as 
mesenchymal or non-parenchymal cells (NPC). HC makes about 78% and NPC about 6% of 
the liver tissue volume. The last 16% of the liver tissue volume are covered by the 
extracellular space. (Hiromi, et al., 2009) Figure 1 gives a good overview about the whole 
liver architecture and the localization of the different cell types in the liver. As these thesis 
concentrates mainly on three cell types (HC, EC, KC), the following paragraphs give a 
detailed look in their individual functions and characteristics. 
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Figure 1: Liver architecture and localization of the different cell types in the liver. 
Source: (Shoelson, et al., 2007) 
 
Hepatocytes (HC) 
Structurally, HC are large polygonal cells with a 25-30 µm cross section (Grisham, 2009) and 
six or more surfaces which border on bile canaliculi and the perisinusoidal space. HC are the 
power stations of the liver as they are equipped with the machinery necessary to carry out all 
the complex vital functions such as biotransformation. Additionally, HC produce 
approximately 15 ml bile per kg body weight and day in humans. (Malarkey, et al., 2005) 
 
Endothelial cells (EC) 
Specifically, the sinusoidal EC act as a kind of barrier to protect the HC from direct contact 
with blood. They have fenestrae, a lack of basal lamina and are able to transfer molecules 
and particles by endocytosis. Further functions include filtration of fluids, solutes and 
particles between the blood and space of Disse. (Malarkey, et al., 2005) 
 
Kupffer cells (KC) 
KC are located within the lumen of the liver sinusoids and as a consequence, they are at first 
exposed to materials absorbed from the gastrointestinal tract. These cells are defined as 
resident macrophages responsible for phagocytosis, antigen presentation and production of 
pro-inflammatory cytokines. Once KC are activated by pathogenic agents, they release 
inflammatory mediators, growth factors and reactive oxygen species (ROS). Therefore, KC 
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play an important role in the innate immune response and acute hepatic injury. Furthermore, 
KC express a variety of toll like receptors (TLRs), such as TLR4, which is involved in uptake 
and clearance of endotoxins, production of cytokines and ROS. (Hiromi, et al., 2009) 
 
Stellate cells (SC) 
The so called fat-storing cells can be found in the space of Disse and are the major source 
for the production of extracellular matrix. Their functions range from storage of vitamin A to 
the development of hepatic fibrosis in response to injury. Activated SC transform to 
myofibroblasts which express desmin and smooth muscle actin filaments. (Malarkey, et al., 
2005; Hiromi, et al., 2009) 
 
All cell types of the liver act together. Accordingly, extensive alcohol consumption, unhealthy 
diet, drugs and xenobiotics mostly affect all cells and lead to profound deregulations of 
cellular processes. The alterations may lead to the development of liver cancer which is 
described in detail below. 
 
1.2 Hepatocarcinogenesis 
1.2.1 Carcinogenesis 
It is well known that tumor development is a multistep process which includes initiation, 
promotion and progression. Initiation often occurs after a short exposure to a potent initiating 
agent such as a genotoxic carcinogen. Characteristic for the first stage is that it is an 
irreversible, heritable process which needs just a short period of time. The next stage 
(promotion) is a slow, gradual process which includes a longer exposure to the promoting 
agents. In many rodent tests, NGC have been demonstrated to act in a tumor promoting 
way. Tumor promotion can be described as the selective amplification of preneoplastic cells 
by increases in cell proliferation and/or decreases of apoptosis. Finally tumor progression 
originates from the acquisition of additional mutations and progredient acquisition of a 
malignant phenotype. (Ruddon, 2007) 
 
The genetic alterations that cause the progressive transformation of normal human cells into 
highly malignant derivatives have been described by Hanahan and Weinberg in their review 
of 2011 “Hallmarks of cancer: The next generation”. Eight essential alterations in cell 
physiology may collectively lead to malignant growth: (1) on-going proliferative signalling, (2) 
evading growth suppressors, (3) apoptosis, (4) unlimited replicative potential, (5) 
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angiogenesis, (6) tissue invasion and metastasis, (7) modifying of cellular metabolism to 
support neoplastic proliferation and (8) avoiding immune destruction. (Hanahan, et al., 2011)  
 
1.2.2 Hepatocellular carcinoma (HCC) 
HCC accounts for about 85% of all primary liver cancers and is one of the most prevalent 
life-threatening human cancers worldwide. An increase of cases is observable and prognosis 
is very poor despite recent advances in the understanding of the pathogenesis and some 
progress in treatment. (Pogribny, et al., 2008; Schattenberg, et al., 2011; Breuhahn, et al., 
2006; Frenette, et al., 2012 )  
 
The most remarkable risk factors associated with HCC are chronic virus infection with 
hepatitis B and C virus, exposure to environmental chemicals, alcoholism, obesity and 
cirrhosis of the liver. (Pogribny, et al., 2008) In most cases, HCC evolves due to a complex 
interaction between multiple risk factors and not due to a single cause. (Leong, et al., 2005) 
 
1.2.3 Cirrhosis 
In 80-90% of patients, cirrhosis is the underlying disease of HCC. (Leong, et al., 2005) 
Cirrhosis is characterized by replacement of the parenchyma with dense fibrous scars by 
progredient fibrosis and angiogenesis. This results in profound alterations of the normal 
hepatic architecture. Growth regulating factors such as cytokines, hepatocyte growth factor 
(HGF), epithelial growth factor (EGF), transforming growth factor-α (TGFα) and tumor 
necrosis factor (TNF) play important roles in the formation of regenerative nodules within 
scarred liver tissue. (Hiromi, et al., 2009) 
 
The knowledge about the biology of cancer grows every day and can be seen as a large 
renewing handbook used to find further treatment possibilities and therapies. Rather new 
thematic priorities in cancer research are inflammation and signalling pathways which are 
also of special interest for this thesis and discussed in the next two chapters. 
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1.3 Inflammation and cancer 
1.3.1 The link between inflammation and liver cancer 
In recent years, cancer research highly focuses on the influence of chronic inflammation in 
tumor promotion and progression. It is already known that chronic inflammation contributes 
to a tumor supporting microenvironment which plays a huge role in the neoplastic process. In 
the tumor, there is a shift from cytokines with antitumor activity/immunity towards cytokines 
that favour tumor progression. (Lin, et al., 2007) The specific functions and pathways of four 
pro-inflammatory factors, which are also related to the development of HCC, are described 
below. 
 
 
Figure 2: Molecular pathways connecting inflammation and HCC development.  
IL-6, COX-2 and TNFα (surrounded) are important key factors for linking inflammation and liver cancer over the 
NF-κB and JAK/STAT pathways. Source: (Berasain, et al., 2009) 
 
  
 
13 
 
1.3.2 Tumor necrosis factor-alpha (TNFα) 
Characteristics 
TNFα is a pro-inflammatory cytokine and regulates a cascade of cytokines, chemokines, 
adhesions, MMPs and angiogenesis. (Coussens, et al., 2002) It is also suggested that TNFα 
contribute to tumor initiation by enhancing the production of reactive oxygen species. Further 
functions of TNFα are promotion of metastasis and reduction of immune surveillance by 
suppressing T cell responses and the cytotoxic activity of activated macrophages. (Lin, et al., 
2007) 
 
Pathway 
The production of TNFα by tumor cells or inflammatory cells in the tumor microenvironment 
promotes tumor cell survival through the NF-κB pathway (Figure 2). TNFα activates through 
its receptor TNFR1 the key inflammatory transcriptional regulator NF-κB which in turn plays 
an important role during neoplastic transformation in the liver. (Berasain, et al., 2009) 
 
1.3.3 Interleukin 6 (IL-6) 
Characteristics 
IL-6 is described as a strong pleiotropic inflammatory cytokine that acts as an angiogenic, 
growth-promoting and anti-apoptotic factor. (Lin, et al., 2007) Additionally, IL-6 has been 
shown to play an important role in liver cancer development caused by carcinogens. 
(Zamarron, et al., 2011)  
 
Pathway 
The IL-6 signalling pathway (Figure 2) starts at the heterodimeric receptor complex 
consisting of IL-6Rα and glycoprotein 130 (gp130). The active gp130 induces tyrosine 
phosphorylation of the `signal transducers and activators of transcription´ (STAT) proteins 
STAT1 and STAT3. Phosphorylation of the STAT proteins by the janus kinase 1 (JAK1) 
enables dimerization and translocation to the nucleus where IL-6 target genes get activated. 
The genes activated are involved in cell cycle progression and suppression of apoptosis 
which explains the key role of IL-6 in tumorigenesis. (Lin, et al., 2007) There is also the fact 
of a complex relationship between the NF-κB and STAT3 pathway. An active NF-κB pathway 
leads to the expression of IL-6 and COX-2 and this again are important activators of STAT3 
signalling. (Berasain, et al., 2009) 
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1.3.4 Cyclooxygenase 2 (COX-2) 
Characteristics 
COX-2 is an inducible cyclooxygenase and gives response to numerous intracellular and 
extracellular stimuli in a pro-inflammatory way. (Williams, et al., 1999) Chronic liver 
inflammation and cirrhosis often show increased COX-2 expression levels. Furthermore, 
enhanced prostaglandin 2 (PGE2) levels are existent in liver cancer cells which supports 
tumor cell proliferation, invasion, metastasis, survival and angiogenesis. (Berasain, et al., 
2009) 
 
Pathway 
COX-2 converts arachidonic acid to prostaglandins such as PGE2 (Figure 2) which in turn 
contributes to inflammatory response in damaged tissues. (Coussens, et al., 2002) Various 
researchers have found an interaction between COX-2 and epidermal growth factor receptor 
(EGFR) signalling pathways. PGE2 is able to transactivate the EGFR receptor which 
includes binding of PGE2 to its EP1 receptor. Carcinogenic liver cells often show a persistent 
activation of the EGFR and its pathway. (Berasain, et al., 2009) 
 
1.3.5 Inducible nitric-oxide synthase (iNOS) 
Characteristics 
Nitric oxide (NO) is a free radical with a short half-life and functions as a mediator of chronic 
inflammation and as a modulator in tumorigenesis by regulating cell proliferation, survival, 
angiogenesis and DNA repair. The product NO originates from the conversion of L-arginine 
to L-citrulline catalysed by the calcium independent enzyme iNOS. Interestingly, patients with 
cirrhosis and HCC show increased NO plasma levels. However, the detailed mechanism how 
iNOS interacts with signalling pathways in hepatocarcinogenesis is not completely 
understood and needs further investigations (Ikeguchi, et al., 2002; Calvisi, et al., 2008) 
 
Pathways 
The influence of NO in various pathways correlates with its concentration and depends on 
the interaction with other molecules such as free radicals, metal ions, proteins and target 
cells. NO is able to activate the tumor protein 53 (p53) pathway and additionally induces 
oncogenic mutations in the p53 gene. In general, p53 is involved in cell cycle regulation and 
acts as a tumor suppressor gene. Besides, iNOS causes unlimited cell growth by inactivating 
the retinoblastoma protein (pRb) pathway. Normally, pRb is a tumor suppressor and should 
prevent cells from unrestrained growth. (Calvisi, et al., 2008) 
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1.4 The role of mitogen-activated protein kinases (MAPKs) in HCC 
1.4.1 Function of MAPKs 
The MAPKs belong to a family of serine/threonine kinases which consists of four subfamilies: 
Jun N-terminal kinase (JNK), extracellular signal-regulated kinases 1 and 2 (ERK1/2), p38 
MAPK and ERK5. Their main function is the transduction of extracellular stimuli (cytokines, 
stress signals, growth factors) in a wide range of cellular responses such as cell proliferation, 
cell survival and death, gene expression, differentiation and migration. MAPKs play key roles 
in embryonic development, tissue homeostasis and inflammation. Besides regulating these 
complex cellular functions, the MAPK signalling pathways are often deregulated in many 
types of human cancers such as HCC. (Min, et al., 2011; Chang, et al., 2001)  
 
1.4.2 Activation of the MAPK signalling pathway 
The MAPK signalling pathway proceeds over a multi-stage signal cascade which consists of 
phosphorylation events of three consecutive components: MAPK kinase kinase (MAP3K), 
MAPK kinase (MAP2K) and MAPK. The enzymes catalyse the phosphorylation events on the 
threonine and tyrosine motif. Different external stimuli trigger the activation of MAP3K which 
activates MAP2K which in turn finally activates MAPK. The outcome is that MAPK activate 
several transcription factors such as c-Myc or c-Fos. (Min, et al., 2011) In the following 
paragraph the characteristics and features of the ERK pathway are described. 
 
1.4.3 The ERK pathway 
Although ERK1 and ERK2 are serine and threonine kinases with almost different functions, 
they share more than 80% of its similarity in protein sequences. Ligands bind to extracellular 
N-terminal domain of tyrosine kinases receptors such as EGFR. After that event, EGFR is 
able to form dimers and induces phosphorylation of the intracellular C-terminal region that 
binding sites for adaptor proteins are accessible. In further consequence, Ras GTPases get 
activated which leads to the activation of Raf kinases. These kinases phosphorylate the dual-
specificity kinases MEK1 and MEK2 which in turn phosphorylate ERK1 and ERK2 on 
threonine and tyrosine residues. Finally active ERK1 and ERK2 regulate a wide variety of 
cellular processes especially cell proliferation and prevention of cell death. (Min, et al., 2011) 
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1.4.4 The role of ERK pathway in HCC 
Phosphorylated ERK levels are increased in many human HCC samples. Furthermore, 
constitutively activated ERK1 and ERK2 play an essential role for the proliferation and 
invasion of human HCC cells. In rodents, the genes Ras and Raf are significantly 
upregulated in foci of altered hepatocytes, precancerous nodules and HCCs. Recent studies 
with a siRNA-mediated knockdown of ERK2 show elimination of liver cell proliferation and 
DNA replication in vitro. (Min, et al., 2011) Moreover, the ERK pathway is involved in the 
transcriptional regulation of PB induced CYP2B gene expression in rats. (Lu, et al., 2009)  
 
The way how NGC may act over the ERK pathway was one important question to be partially 
answered in that thesis. The following paragraphs should give a short summary about NGC 
examined in this thesis. 
 
1.5 Carcinogens 
1.5.1 Genotoxic carcinogens (GC) versus non-genotoxic carcinogens (NGC) 
NGC can be distinguished from GC by their mode of action. Most GC bind covalently to DNA 
and damage is caused by the formation of DNA adducts. The cell usually reacts to damage 
with repair mechanisms, cell cycle arrest or induction of apoptosis. If these lesions are not 
correctly repaired, mutations lead in further consequence to the formation of tumors. The 
mode of action of NGC is more complex, excludes DNA damaging but includes a wide 
variety of cellular processes such as proliferation of peroxisomes or endoplasmatic reticulum, 
induction of replicative DNA synthesis, suppression of apoptosis and/or oxidative stress. (van 
Delft, et al., 2004; Mathijs, et al., 2009) 
 
1.5.2 Characteristics of NGC 
The carcinogenic potential of NGC is not easy to study due to their tissue and species 
specificity. This is aggravated by the fact that they act among others as tumor promoters, 
receptor mediators, immune suppressors or inducers of inflammatory responses. The usual 
way to detect and study NGC is by performing 2-year cancer bioassays with rodents. 
(Hernàndez, et al., 2009) The disadvantages of chronic rodent bioassays consist of a high 
false positive rate, great costs, huge number of animals and a long study period. That is the 
reason why the development of efficient in vitro assays and the search for reliable 
biomarkers to predict the carcinogenicity of NGC awake more and more interest. (Mathijs, et 
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al., 2009) The subsequent paragraphs supplies details about the NGC phenobarbital, 
cyproterone acetate and wyeth-14,643 as they are the NGC examined in this thesis.  
 
1.5.3 Phenobarbital (PB) 
PB belongs to the family of barbiturates (Figure 3) and was established for medical purpose 
in 1912. It is a common drug for treatment of epilepsy in developed countries and a well-
studied liver tumor promoter in rodents. PB causes liver hyperplasia and hypertrophy. 
Additionally, a promoting dose of PB leads to increased DNA synthesis, decreased apoptosis 
in murine HC and initially stimulates HC proliferation. On a genetic level, PB induces 
expression of various cytochrome P450 enzymes (CYP) and causes altered transcriptional 
regulation. This is mediated through pregnane X receptor (PXR) and constitutive androstane 
receptors (CAR). Chronic CAR activation in response to PB results in hepatocarcinogenesis. 
(Kwan, et al., 2004; Waterman, et al., 2010; Phillips, et al., 2009) 
 
 
 
 
 
 
 
 
Figure 3: Chemical structure of PB.  
Name: 5-ethyl-5-phenylbarbituric acid.  
Source: (Kwan, et al., 2004) 
 
1.5.4 Cyproterone acetate (CPA) 
CPA is per definition an antiandrogen which acts via competitive inhibition of androgen 
receptors. It is a synthetic derivative from hydroxyprogesterone (Figure 4) which has also 
progestational and antigonadotropic activity. Medically CPA is very often used to treat 
hormonal diseases in women such as hirsutism, androgenic alopecia, acne and seborrhoea. 
In men, it is applied in high doses to treat prostate carcinoma, sexual drive disorders or is 
used for gender transformation from male to female. (Kasper, 2001) 
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The application of CPA in high dosages is necessary for the treatment of malignant prostate 
diseases. However, high doses of CPA correlate with severe hepatotoxicity. This leads to 
liver cell proliferation and enlargement of the liver via hyperplasia. Furthermore, the 
antiandrogen predisposes hepatocytes to undergo apoptosis. DNA damage in the liver is 
also a consequence of CPA administration. Transcriptionally, CPA is able to activate the 
nuclear receptor PXR and induce hepatic CYPA3A in rat and human hepatocytes. (Savidou, 
et al., 2006; Schuetz, et al., 1998) 
 
 
Figure 4: Chemical structure of CPA 
Name: 6-chloro-17-acetoxy-1,-2-methylenepregna-4,6-diene-3,20-dione. 
Source: http://www.lookchem.com/cyproterone-acetate/ 
 
1.5.5 Wyeth-14,643 (WY) 
WY is a hypolipidemic drug (Figure 5) and belongs to the group of peroxisome proliferators 
(PP). Generally, PP are NGC which induce numerical increases of peroxisomes in HC, 
induction of peroxisomal enzymes and CYP, liver cell proliferation and inhibition of apoptosis 
in rodents. Long-term treatment of rodents with WY leads to liver hypertrophy, hyperplasia 
and tumor formation. (Trapp, et al., 2007) WY acts via the nuclear receptor PPARα (see 
section 1.7.2). Interestingly, cell proliferation, peroxisome proliferation or enzyme induction, 
and liver tumor formation were not observable in PPARα-knockout mice which were treated 
with WY. This results lead to the conclusion that PPARα plays an important role in WY-
induced hepatocarcinogenesis. (Suga, 2004; Gonzalez, et al., 2008) 
  
  
 
19 
 
 
 
Figure 5: Chemical structure of WY-14,643  
Name: 4-chloro-6-(2,3-xylidino)-pyrimidinylthioacetic acid. 
Source: http://www.chemicalbook.com/ChemicalProductProperty_DE_CB9345027.htm 
 
The aims of this thesis are to provide a better understanding of the mode of action of NGC 
and to search for markers indicating their carcinogenic action. As binding to different NR and 
induction of CYP isoenzymes are key features of many NGC, further information on these 
aspects are provided in the next two chapters.  
 
1.6 The cytochrome P450 superfamily (CYP) 
The CYP enzymes can be defined as heme proteins which catalyse phase I metabolism of 
xenobiotics such as carcinogens, drugs and environmental pollutants but also of fatty acids, 
steroids, prostaglandins and bile acids. CYP are located in the endoplasmic reticulum of HC 
and in the epithelium of the jejunum, lungs, kidney and other organs as well as in the brain. 
(Carver, 2007) An important characteristic is their broad and overlapping substrate 
specificity. On the one hand, CYP mediate through detoxification a protective mechanism but 
on the other hand they are also able to activate substrates to carcinogenic, mutagenic and/or 
cytotoxic products. (Denison, et al., 1995) In the following the focus lays on CYP enzymes 
which are induced by PB, CPA and/or WY. 
 
1.6.1 NGC-induced CYP enzymes 
It is well known that treatment of rodent HC with PB highly increases the transcription rate of 
CYP2B1/2 and to lower extent of CYP3A and CYP2C genes. Gene expression of CYP2B1/2 
often serves as positive control for the PB effect. The human and rat CYP3A forms are 
induced by different steroidal hormones. Different studies revealed that anti-hormone 
representatives such as the anti-mineralocorticoid spironolactone and the antiandrogen CPA 
were able to induce hepatic CYPA3A in rat and human hepatocytes. The mRNA levels of 
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CYP4A1 are induced by PPs such as WY. In this context, Cyp4a1 catalyse peroxisomal ß-
oxidation of fatty acids and induction of microsomal lauric acid ω-hydroxylase activity. 
(Denison, et al., 1995; Schuetz, et al., 1998)  
 
1.7 Nuclear receptors (NR) 
NR are a superfamily of transcription factors which can be activated by various ligands 
including hormones, lipids and xenobiotics. Their main function is to regulate many cellular 
processes such as development, growth and homeostasis. It is anticipated that permanent 
activation of NR, as occurring during continuous application of NGC, may lead to permanent 
deregulation of intracellular pathways which may trigger hepatocarcinogenesis. (Shah I., 
2011) 
 
The NR superfamily consists of four classes which are based on their dimerization properties 
and features of binding to DNA. Class I receptors represent the steroid hormone receptors. 
When induced by ligands, they form homodimers and bind to the response elements in the 
promoter region of target genes. Class II receptors form heterodimers with the retinoid X 
receptor (RXR) before interacting with target genes. Noteworthy is that Class II receptors 
such as PXR and CAR were identified as xenobiotic sensors which induce enzymes involved 
in phase I detoxification, like CYP enzymes. RXR belong to Class III receptors which are 
characterized by having no ligands and binding as homodimers. NR belonging to Class IV, 
such as the liver receptor LRH1, act as monomers. (Lu, et al., 2006; Pirola, 2008; 
Mangelsdorf, et al., 1995) 
 
1.7.1 Class I receptors 
Steroid hormone receptors occur in the inactivated state as monomers bound to heat shock 
proteins in the cytosol. Ligand binding leads to dissociation of the heat shock proteins, homo-
dimerization and translocation to the nucleus to bind to hormone response elements (HRE). 
In general, they play a crucial role in stress response, metabolism, immune function, growth, 
development and reproduction. (Lu, et al., 2006; Mohler, et al., 2008) 
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Mineralocorticoid receptor (MR), progesterone receptor (PGR) and androgen receptor (AR) 
MR is highly expressed in epithelial tissues and its principal ligand is aldosterone. PGR can 
be primarily found in the reproductive tract and progesterone serves as ligand. AR is mainly 
expressed in prostate, skeletal muscle, liver and central nervous system. Free testosterone 
and dihydrotestosterone bind to intracellular AR and lead to its activation. (Mohler, et al., 
2008) 
 
Estrogen receptor (ER) 
In the last two decades it has been recognized that ERα is not the only ER but that 
additionally ER exist, such as ERβ. ERα and ERβ are not isoforms of each other but are 
different proteins. (Couse, et al., 1999) Both receptors can be found to be mainly expressed 
in the reproductive tract and further in liver, pituitary, hypothalamus, bone and cardiovascular 
system. After binding of the hormone estrogen to the ER, a conformational shift leads to the 
transcriptionally active form. (Weis, et al., 1996) 
 
1.7.2 Class II receptors 
Pregnane X receptor (PXR) 
PXR, also often designated as NR1I2, is highly expressed in liver and intestine and less 
expressed in lungs and kidneys. PXR can be found in the cytoplasm were it is associated 
with a protein complex. As PXR is equipped with very large binding pockets it can bind many 
different ligands including the pharmaceutical drugs RU486 and rifampicin but also specific 
bile acids and hormones. After activation through ligand binding, PXR dimerizes with RXRα 
and translocates to the nucleus to trigger activation of its target genes. CYP3A is among 
other phase I metabolism genes known to be transcriptionally regulated by PXR. (Pirola, 
2008; Tien, et al., 2006) Additionally, studies of PXR-null mice show that PXR causes 
downregulation of several hepatic proteins during inflammation. (Teng, et al., 2004) 
 
Constitutive androstane receptor (CAR) 
CAR (NR1I3) is detected mainly in the liver but also to a smaller extent in extrahepatic 
tissues such as the intestine. Well known agonists for CAR are the anti-seizure drug PB and 
xenobiotics such as 1,4-Bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP). The hormones 
androstanol and androstenol block the constitutive activity of CAR by acting as inverse 
agonists. (Pirola, 2008) 
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This receptor shows unique activation mechanisms compared with other orphan receptors. 
On the one hand, after direct ligand binding, CAR translocates to the nucleus, 
heterodimerizes with RXRα and finally binds to the phenobarbital responsive enhancer 
modules (PBREM). On the other hand, there is strong evidence that CAR gets activated by 
PB via indirect ligand-independent pathway. Results from different studies lead to the 
assumption that PB may activate CAR through indirect mechanisms such as co-activation 
and phosphorylation. (Moore, et al., 2000; Tolson, et al., 2010) 
 
CAR primarily regulates transcription of CYP2B and other drug metabolism genes. Relevant 
to mention is the role of CAR in the promotion of tumor formation. A study including 
treatment of mice with the tumor initiator diethyl nitrosamine (DEN) followed by treatment 
with PB for 36 weeks showed that, in contrast to the wild type mice, the CAR knockout mice 
did not develop any HCC. (Pirola, 2008; Tien, et al., 2006) 
 
Peroxisome proliferator-activated receptor alpha (PPARα) 
PPARα is one of the three members of the peroxisome proliferator-activated receptor family 
and is highly expressed in rodent liver and kidney. Human HC express PPARα at 
approximately 5-10% of the levels found in rodent HC. Typical PPs such as WY activate 
PPARα that act after ligand binding like other type II NR by heterodimerization with RXRα. 
The heterodimer binds to the peroxisome proliferator response element (PPRE) were it 
regulates transcription of a large number of genes involved in peroxisome proliferation and 
the ß-oxidation of fatty acids. Furthermore, PPARα is known as a mediator in cancer 
development. Studies showed that the chronic treatment of wild type mice with WY cause an 
increased cell proliferation, upregulation of pro-inflammatory cytokines, decreased apoptosis 
and as a consequence a high incidence of liver tumors. In contrast, no liver tumor formation 
could be observed in PPARα-null mice. (Holden, et al., 1999; Gonzalez, et al., 2008)  
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2. Aims 
So far hepatocarcinogenesis is considered to be a mere epithelial disease. However, it is 
increasingly recognized that mesenchymal cells contribute to the development of HCC as 
well. It is unknown whether NGC act on the hepatic mesenchyme. The main purpose for that 
project was the investigation of NGC effects on different liver cell types. The studies included 
the characterization of the expression levels of NR, growth factors and chemo-/cytokines in 
parenchymal (HC) and mesenchymal (EC, KC, SC) cells in order to improve our 
understanding of the mode of action of NGC.  
 
The following points were chosen as important aims for this project: 
 
(1) The induction of some CYP will proof that a given NGC exerts effects on a cell. In 
order to get to know on which liver cell type NGC may act, the expression levels of 
various CYP were determined in untreated and NGC treated primary liver cells (HC and 
NPC).  
 
(2) The activation of NR may play a key role in NGC-driven hepatocarcinogenesis. 
Therefore, the basal mRNA levels of various NR (CAR, PXR and PPARα) were 
determined in untreated primary liver cell types (HC, EC and KC). It was also studied 
whether several NGC, such as CPA, PB and WY, have effects on the expression level 
of their targeted NR in HC and NPC. Furthermore, chemical inhibitors of CAR and PXR 
were used to gain more information about the NR involved in the action of NGC. 
 
(3) As the carcinogenic action of NGC may also include interactions between the 
hepatic parenchyme and mesenchyme, the effects of the secretome of NPC on HC and 
vice versa were checked. The cells and their supernatant derived from livers of rats 
treated with PB or solvent. The mRNA levels of the inflammatory mediators TNFα, IL-6, 
COX-2 and iNOS were determined. Furthermore, the release of TNFα from HC and NPC 
was measured via ELISA.  
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(4) The effects of in vivo application of NGC on transcription patterns of HC and NPC 
were analysed by using the Gene Chip technology.  
 
(5) The ERK pathway may act as a potent signalling pathway involved in the mode of 
action of NGC. Therefore, expression levels of components of this pathway were 
determined on transcriptome and/or protein levels in liver cells treated with PB or 
CPA.  
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3. Materials and Methods 
3.1 Reagents 
Table 1: Reagents and Supplier. 
Reagent Supplier 
10 mM dNTP Mix Fermentas (Burlington, Ontario) 
10x Complete Mini (protease inhibitor, PMSF) Roche (Indianapolis, Indiana) 
2x Go Taq Green Master Mix (2x MM) Promega (Madison, WI) 
3H-Thymidine ARC (St. Louis, MO) 
5x Biorad protein assay Biorad (Hercules, CA) 
6x Loading Dye Fermentas (Burlington, Ontario) 
Acrylamid Biorad (Hercules, CA) 
Agarose Biozym (Hessisch Oldendorf, Germany) 
Ammonium-persulfate (APS) Sigma (St. Louis, MO) 
Ascorbat Merck (Darmstadt, Germany) 
Bovine serum albumin (BSA) Sigma (St. Louis, MO) 
Calciumchloride Merck (Darmstadt, Germany) 
Chloroform Merck (Darmstadt, Germany) 
Collagenase Worthington (Lakewood, NJ) 
Cyproterone acetate (CPA) Bayer Schering Pharma (Berlin, Germany) 
Detection reagent for western blotting GE Healthcare (Uppsala, Sweden) 
Dexamethasone Serva (Heidelberg, Germany) 
Diethylpyrocarbonate (DEPC) Sigma (St. Louis, MO) 
Dimethylsulfoxide (DMS) Sigma (St. Louis, MO) 
Ethanol Merck (Darmstadt, Germany) 
Ethidiumbromide Sigma (St. Louis, MO) 
Ethylenediaminetetraacetic acid (EDTA) Sigma (St. Louis, MO) 
Fetal Calf Serum (FCS) PAA (Pasching, Austria) 
Formalin Merck (Darmstadt, Germany) 
GeneRuler 50 bp DNA marker Fermentas (Burlington, Ontario) 
Gentamycin Serva (Heidelberg, Germany) 
Glucagon Sigma (St. Louis, MO) 
Glucose Merck (Darmstadt, Germany) 
Glutamax Invitrogen (Carlsbad, California) 
Glycerin Sigma (St. Louis, MO) 
Glycin Sigma (St. Louis, MO) 
Heparin sodium salt Serva (Heidelberg Germany) 
HEPES Sigma (St. Louis, MO) 
Hexamer Primers Fermentas (Burlington, Ontario) 
Igepal CA 630 Sigma (St. Louis, MO) 
Insulin Sigma (St. Louis, MO) 
Isopropanol Merck (Darmstadt, Germany) 
KCl Merck (Darmstadt, Germany) 
Mercaptoethanol Sigma (St. Louis, MO) 
Methanol Merck (Darmstadt, Germany) 
MMLV reverse transcriptase Fermentas (Burlington, Ontario) 
N,N,N´,N´-Tetramethylendiamine (TEMED) Sigma (St. Louis, MO) 
Na2HPO4 Merck (Darmstadt, Germany) 
Na3VO4 Sigma (St. Louis, MO) 
NaCl Merck (Darmstadt, Germany) 
Na-Deoxycholat Sigma (St. Louis, MO) 
NaH2HPO4*2H2O Merck (Darmstadt, Germany) 
NaOH Merck (Darmstadt, Germany) 
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N-nitrosomorpholine (NNM) Sigma (St. Louis, MO) 
PageRuler prestained protein ladder Fermentas (Burlington, Ontario) 
Penicillin G sodium salt Sigma (St. Louis, MO) 
Penicillin-Streptormycin PAA (Pasching, Austria) 
Percoll GE Healthcare (Uppsala, Sweden) 
Phenobarbital (PB) Sigma (St. Louis, MO) 
Picrotoxin Sigma (St. Louis, MO) 
PK-11195 Sigma (St. Louis, MO) 
Ponceau S Sigma (St. Louis, MO) 
Pyruvate Sigma (St. Louis, MO) 
Recombinant tumor necrosis factor alpha (TNFα) R&D Systems (Minneapolis, Minnesota) 
Skim milk Sigma (St. Louis, MO) 
Sodium dodecyl sulphate  Sigma (St. Louis, MO) 
Streptomycin sulphate salt Sigma (St. Louis, MO) 
Sulforaphane (SFN) Sigma (St. Louis, MO) 
TaqMan® gene expression assays Applied Biosystems (Carlsbad, California) 
TaqMan® universal master mix Applied Biosystems (Carlsbad, California) 
TriFast Peqlab (Erlangen, Germany) 
Triiodthyronin Serva (Heidelberg, German) 
Trizma base Sigma (St. Louis, MO) 
Trypan blue Invitrogen (Carlsbad, California) 
Trypsin Sigma (St. Louis, MO) 
Tween 20 Biorad (Hercules, CA) 
Wy-14,643 (WY) Wyeth/Pfizer (New York, NY) 
 
3.2 Buffers and Solutions 
BSA buffer pH 7.4 (per litre): 
8.3 g NaCl, 0.5 g KCl, 2.4 g HEPES, 6 ml 1M NaOH, 1 g BSA, 10 mg Gentamycin 
 
Collagenase buffer pH 7.5 (per litre):  
6.8 g NaCl, 0.4 g KCl, 1 g glucose, 1 g HEPES, 60 mg penicillin G sodium salt, 100 mg 
streptomycin sulphate salt, 550 mg pyruvate, 294 mg CaCl2 
 
Formalin according to Lillie pH 7.0 (per litre):  
4% formalin, 4 g NaH2HPO4*H2O and 6.5 g Na2HPO4 
 
10x HBSS (per litre): 
80 g NaCl, 4 g KCl, 2g MgSO4*7H2O, 0.6 g KH2PO4, 10 g Glucose, 0.6 g Na2HPO4*2H2O 
 
Laemmli electrophoresis buffer (per litre):  
3 g Trizma base, 14.4 g Glycin, 1 g SDS 
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5x Laemmli loading buffer: 
300 mM Tris/HCl pH 6.8, 60% Glycerol, 10% SDS, 0.025 % bromophenolblue, 7% ß-
mercaptoethanol 
 
Phosphate buffered saline (PBS) pH 7.4 (per litre):  
1.44 g Na2HPO4, 2.62 g NaH2HPO4*2H2O, 5.68 g NaCl 
 
PBST: 
PBS supplemented with 0.5% Tween 20  
 
Stock Isoosmotic Percoll (SIP): 
90% (=21.6 ml Percoll), 10% (=2.4 ml) 10x HBSS 
 
Stock percoll solution (SPS): 
90% Percoll and 10% 10 fold PBS 
50% Percoll-solution:  50% SPS + 50% PBS 
49% Percoll solution:  49% SPS + 51% PBS 
25% Percoll-solution:  25% SPS + 75% PBS 
 
Perfusion buffer pH 7.4 (per litre):  
6.8 g NaCl, 0.4 g KCl, 1 g glucose, 1 g HEPES, 60 mg penicillin G sodium salt, 100 mg 
streptomycin sulphate salt, 12.4 mg heparin sodium salt, 550 mg pyruvate 
 
RIPA buffer:  
500 mM NaCl, 50 mM Trizma base pH 7.4, 0.1% SDS, 1% NP-40, 0.5% Na-Deoxycholate, 
0.5 mM Na3VO4, 1 mM PMSF  
 
Tris-borat-EDTA buffer (TBE) (per litre):  
10.8 g Trizma base, 5.5 g boric acid, 4 ml 0.5 M EDTA pH 8.0 
 
Tris buffered saline (TBS) pH 7.6:  
0.05 M Trizma base, 0.3 M NaCl 
 
TBST: 
TBS supplemented with 0.5% Tween 20  
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Transfer buffer (per litre):  
3 g Trizma base; 14.4 g Glycin, 5% Methanol 
 
3.3 Media 
3.3.1 Media for hepatocytes 
Wash medium: 
Minimum essential medium (Sigma, St. Louis, MO) supplemented with 20 mM HEPES, 10 µg 
/ ml Gentamycin, 10 µl / ml Glutamax 
 
Culture medium (WEII): 
Williams-Medium E (Invitrogen, San Diego, CA) supplemented with 20 mM HEPES, 10 µg / 
ml Gentamycin, 10 µl / ml Glutamax, 0.151 mM Ascorbat, 6.7 nM Insulin,  0.7 nM Glucagon, 
10 nM Triiodthyronin, 100 nM Dexamethason 
 
Plating medium: 
WEII supplemented with 10% FCS 
 
3.3.2 Media for non-parenchymal cells 
Plating medium: 
RPMI 1640 (Sigma, St. Louis, MO) supplemented with 10% FCS and 10 µg / ml Gentamycin 
 
Culture medium: 
RPMI 1640 (Sigma, St. Louis, MO) supplemented with 10 µg / ml Gentamycin 
 
Medium for endothelial cells:  
EBM2 (Lonza, Basel, Switzerland) was applied with EGM-2MV (Lonza) 
 
3.3.3 Media for HepG2 cell line 
MNP supplemented with 10% FCS 
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3.4 Animals and treatment 
SPF Wistar rats were kept at the ‘Decentralized Biomedical Facilities of the Medical 
University of Vienna’ under standardized “specific pathogen free” (SPF) conditions. The 
protocol was approved by the Austrian Ethics committee. 
 
Short-term PB treatment: 
Male SPF Wistar rats, 8-12 weeks old, were treated with a single dose of PB (50 mg/kg body 
weight dissolved in autoclaved tap water) by gavage. Perfusion of the livers occurred 24 
hours after treatment. The control group was treated with tap water by gavage. 
 
Long-term PB treatment: 
Male SPF Wistar rats, 8-12 weeks old, were treated 14 days with PB (50 mg/kg body weight) 
via drinking water. The control group received tap water only. 
 
Short-term CPA treatment: 
Female Wistar rats, 8-12 weeks old, were treated with a single dose of CPA (100 mg/kg body 
weight dissolved in corn oil) by gavage. The control group was treated with corn oil by 
gavage. Perfusion of the livers occurred 24 hours after treatment.  
 
Long-term CPA treatment: 
Female Wistar rats, 8-12 weeks old, were treated 6 days with a single dose of CPA per day 
(100 mg/kg body weight dissolved in corn oil) by gavage. The control group was treated 6 
days with a single dose of corn oil per day by gavage. 
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3.5 Liver perfusion 
The livers of treated and untreated rats were perfused with collagenase by the colleagues 
Sandra Sagmeister or Marzieh Nejabat. After the perfusion the softened liver was put into 20 
ml of ice cold wash medium. To get the cells out of the liver capsule, the liver was cut more 
times with a sterile scissors and the cells were shaken out into the wash medium. The 
resulted cell suspension was filtered through a mesh with 105 µm pores (Polyester precision 
mesh). This was repeated 3-4 times with fresh and cooled wash medium using a total 
volume of 100 ml wash medium until no more cells could be collected. Finally the filtered cell 
suspension was mixed and divided in two Falcons for a consistent cell separation (see 
section 3.6).  
 
3.6 Cell separation and cell culture 
As a first step to separate primary HC from NPC, the obtained cell suspension from the 
perfused liver was centrifuged at 500 rpm for 5 minutes at 4°C. The supernatant was taken to 
prepare NPC (see section 3.6.2) whereas the pellet was taken for purification of primary HC 
(see section 3.6.1). 
 
3.6.1 Isolation and culture of primary hepatocytes 
Isolation of primary HC: 
After the first centrifugation step, the obtained cell pellet was resuspended with 20 ml wash 
medium and centrifuged at 300 rpm for 5 minutes at 4°C. In the meantime the SIP was 
prepared by mixing 21.6 ml Percoll with 2.4 ml 10x HBSS. The cell pellet was resuspended 
in 25 ml wash medium and mixed well with 24 ml SIP. To separate vital from dead primary 
HC, the suspension was centrifuged at 500 rpm for 10 minutes at 4°C. Afterwards the 
supernatant was discarded carefully and the pellet was purified from percoll by resupension 
with 40 ml wash medium and centrifugation at 500 rpm for 5 minutes at 4°C. If the pellet was 
split in two Falcons, they were combined by resupension in a final volume of 25 ml wash 
medium and the last centrifugation step at 300 rpm for 5 minutes at 4°C. Finally the cell pellet 
was resuspended in 20 ml plating medium and the cell number and vitality was determined 
(see section 3.6.4). 
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Culture of primary HC: 
If not stated otherwise, HC were seeded on rat-tail collagen coated petri dishes in WEII + 
10% FCS. Related to 6-well plates (Falcon) a cell number of 4-5 x 105 per well was used 
whereas for petri dishes with a size of 35 x 10 mm (Falcon) a cell number of 2.5 x 105 was 
used. Change to serum free medium (WEII) occurred 1.5 hours after seeding.  
 
3.6.2 Isolation and culture of non-parenchymal cells 
Isolation of NPC: 
After the first centrifugation step (see section 3.6) the supernatant was centrifuged again at 
2500 rpm for 10 minutes at 4°C. The obtained pellet  was resuspended in 10 ml BSA buffer 
and slowly layered on the top of the percoll gradient (20ml of a 50% Percoll under 19ml of a 
25% Percoll). The Percoll cell suspension was centrifuged for 30 minutes at 2500 rpm at 4°C 
without any acceleration or deceleration to avoid any mixing of the two Percoll solutions. 
After the centrifugation two rings can be seen. One on the top of the gradient which contains 
dead cells and SC; and the second one at the interface of the 25% and 50% Percoll solutions 
which contains KC and EC. The second ring was collected with a pipette, diluted with BSA 
buffer to a volume of 50 ml and centrifuged at 2500 rpm for 10 minutes at 4°C. Finally the cell 
pellet was resuspended in 10-20 ml plating medium (RPMI + 10 % FCS) and the cell number 
and vitality was determined (see section 3.6.4). 
 
Culture of non-parenchymal cells: 
NPC were seeded on collagen-coated petri dishes in RPMI + 10% FCS. If not stated 
otherwise, a cell number of 3 x 106 for 6-well plates was used. After an attachment period of 
1.5 hours, the plating medium was removed and the cells were washed twice with sterile and 
37°C warmed PBS. Afterwards a change to serum free medium was done. 
 
3.6.3 Culture of the HepG2 cell line 
HepG2, a cell line which is epithelial in morphology, was received from ACC (Manassas, 
USA) and cultivated in MNP medium with 10% FCS. They were cultured in T25 flasks 
(Corning) in a cell incubator (New Brunswick Scientific, Innova CO-170) at 37°C and 5% 
CO2. The cells were released from the flask by washing them once with 1 ml trypsin and 
incubating with another 1ml trypsin at 37°C for abo ut 5 minutes. Enzymatic digestion was 
stopped by adding 9 ml medium (MNP + 10% FCS). The cell suspension was pipetted into a 
Falcon and centrifuged for 5 minutes at 800 rpm. After discarding of the supernatant, the 
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pellet was resuspended in medium (MNP + 10 % FCS) and the cell number with a Neubauer 
counting chamber was determined. HepG2 cells were seeded in 6-well plates with a cell 
number of 2 x 105 cells per well. Change of medium was done as required. 
 
3.6.4 Determination of cell number and vitality 
The cell number and vitality of primary HC and NPC was determined by using the trypan blue 
dye exclusion assay. Therefore 50 µl of the cell suspension was mixed with 50 µl of trypan 
blue and a small volume was put into a Neubauer counting chamber. The vitality can be 
calculated by counting the amount of living (not coloured) and dead (blue coloured) cells. 
The living cell number divided by total cell number multiplied with 100 shows the vitality in 
percent. 
 
3.7 In vitro treatment of cells 
3.7.1 Treatment of cells with specific reagents 
Treatment of cells was done in medium without FCS approximately 1.5 – 2.0 hours after 
seeding when cells adhered to the petri dishes. The stock solutions used for treating the cells 
were diluted in their solvent to their final concentration (Table 2) and sterile filtered with a 
Millipore filter (Millex®GP Filterunit 0.22 µm, Express PES membrane). 
 
Table 2: In vitro treatment solutions and applied concentrations. 
Reagent Solvent Stock 
concentration 
Final concentration 
in medium 
Cyproterone acetate DMSO 5 mM 5 µM or 10 µM 
DMSO Medium 100 % 0.2% 
Phenobarbital Medium 100 mM 0.5 mM or 1 mM 
Picrotoxin DMSO 10 mM 10 µM 
PK 11195 DMSO 10 mM 10 µM 
Sulforaphane DMSO 25 mM 10 µM or 25 µM 
TNFα Medium 200 ng 1 ng or 10 ng 
WY-14643 DMSO 10 mM 20 µM 
 
3.7.2 Treatment of cells with supernatants 
For this experiment, in vivo treated and untreated SPF Wistar rats were used. The treatment 
procedure is described in chapter 3.4 Animals and treatment. HC and NPC were separated, 
seeded and kept in culture for 24 hours with a change to fresh RPMI media two hours after 
seeding. The NPC from untreated rats (CO-NPC) were treated with the supernatant, 
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obtained from the HC of the PB treated rats (HC-PB). The HC from untreated rats (CO-HC) 
were treated with the supernatant, obtained from the NPC of the PB treated rats (NPC-PB). 
Untreated cells cultured in RPMI media served as controls. CO-HC, which were treated with 
the supernatant of CO-NPC and vice versa, served as an additional control for the 
experiment. All supernatants were sterile filtered with a Millipore filter (Millex®GP Filterunit 
0.22 µm, Express PES membrane) before treatment. The cells were harvested for RNA 
isolation and further analysis approximately 24 hours after treatment (see sections 3.8.1 and 
3.8.6). 
 
3.8 Methods on RNA level 
3.8.1 RNA isolation from cells 
The supernatant was discarded and cells were washed once with 1x PBS to remove the rest 
of the medium and non-adherent cells. The appropriate amount (for HC 600 µl/well; for NPC 
300 µl/well) of Trifast reagent was pipetted on the cells. The lysed cells were collected with a 
cell scraper and transferred in an Eppendorf tube. Afterwards they were stored at -80°C until 
further usage or RNA was immediately isolated. Therefore a fifth volume chloroform of the 
used Trifast amount was added followed by 15 seconds inverting and 10 minutes incubation 
at room temperature. A centrifugation step was done for 10 minutes at 12,000 x g in a 4°C 
cooled Eppendorf centrifuge. The upper aqueous phase was transferred to a new tube and 
put on ice. The half volume isopropanol of the used Trifast reagent was pipetted on the 
solution and RNA was precipitated overnight at -20°C. 
 
On the next day the RNA-Isopropanol mixture was centrifuged for 10 minutes at 12,000 x g 
and 4°C. The supernatant was discarded gently and t he pellet was washed with the same 
volume ethanol as the used Trifast reagent. This step was followed by 10 minutes 
centrifugation at 14,000 x g and 4°C. The supernata nt was discarded gently and the pellet 
was dried before the RNA was solved in the appropriate amount (for HC 50 µl, for NPC 30 µl) 
of DEPC H2O. Finally the RNA concentration in µg/µl was determined using a Nanodrop 
spectrometer.  
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3.8.2 RNA isolation from tissue 
The appropriate amount of Precellys 1.4 mm ceramic beads (Peqlab, Erlangen, Germany) 
was transferred in RNA isolation tubes (Peqlab, Erlangen, Germany) and 500 µl Trifast was 
added and put on ice. The liquid nitrogen frozen tissue was cut with a scalpel in 50-150 mg 
pieces, the weight was noted and the tissue was put with a forceps into the isolation tubes. 
The tissue was homogenized in with a Precellys® 24 (Peqlab, Erlangen, Germany) for 2x 15 
seconds at 6,000 x g. The following RNA isolation steps with chloroform and isopropanol 
were done as described in section 3.8.1. 
 
3.8.3 Reverse Transcription-PCR (RT-PCR) 
If the RNA concentration was high enough, 1-2 µg RNA was transcribed into cDNA. First the 
RNA was diluted with DEPC H2O in sterile PCR tubes to a total volume of 15 µl. The MM was 
prepared as described in table 3. A volume of 0.625 µl random hexamer primers was added 
to the diluted RNA followed by heating at 70°C for 2 minutes on a thermo block. Back on ice 
9.375 µl of the MM was added, mixed well and placed into a thermocycler (C1000 Thermal 
Cycler, Biorad) with a program of 1 hour at 42°C an d 5 minutes at 94°C to transcribe cDNA. 
The resulted cDNA samples were diluted with DEPC H2O to an end volume of 100 µl and 
stored at -20°C until usage as templates for PCR or  qrt-PCR (see sections 0 and 3.8.6). 
 
Table 3: Master mix for RT-PCR. 
Reagent Volume per sample 
5x buffer 5.000 µl 
dNTPs (10 mM) 1.560 µl 
RNase Inhibitor 0.625 µl 
MMLV 1.000 µl 
DEPC H2O 1.190 µl 
Total volume 9.375 µl 
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3.8.4 Polymerase Chain Reaction (PCR) 
The 1x MM (Table 4) was prepared without adding the template and mixed well. For the 
reaction 24 µl of the 1x MM was pipetted to 1 µl of the appropriate cDNA in a PCR tube.  
 
Table 4: Master mix for PCR. 
Reagent Volume per sample 
Primer forward 1.0 µl 
Primer reverse 1.0 µl 
2x MM 12.5 µl 
DEPC H2O 9.5 µl 
cDNA template 1.0 µl 
Total volume of 1x MM 25.0 µl 
 
 
Finally the tubes were placed into a thermocycler (C1000 Thermal Cycler, Biorad) and the 
standard programme (Table 5) was used with varying cycles. The used oligonucleotides for 
PCR are summarized in table 6. 
 
Table 5: Standard program of PCR. 
Step Repeats Temperature Time 
Cycle 1 1 95°C 5 minutes 
 
Cycle 2 
 ▪ Denaturation 
 ▪ Annealing 
 ▪ Elongation 
 
30 – 42  94°C 
60°C 
72°C 
 
30 seconds 
30 seconds 
30 seconds 
 
Cycle 3 
 
1 
 
72°C 
 
7 minutes 
 
End programme - 4°C ∞ 
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Table 6: Oligonucleotides (rat) for PCR. 
Primer name Sequence Product length Gene-ID (NCBI) 
ERα 5´-ATG-ATG-AAA-GGC-GGG-ATA-CG-3´ 303 bp NM_012689 5´-TGC-CAG-GTT-GGT-CAA-TAA-GC-3´ 
ERβ 5´-GAG-CAA-AGC-CAA-GAG-AAA-CG-3´ 308 bp NM_012754 5´-ACA-TCA-GTC-CCA-CCA-TTA-GC-3´ 
PPARα 5´-TCT-TTC-GGC-GAA-CTA-TTC-GG-3´ 342 bp NM_013196 5´-AAG-GCG-GAT-TGT-TGC-TAG-TC-3´ 
PXR (Nr1i2) 5´-CAA-GGA-TTT-CCG-GCT-ACC-TG-3´ 200 bp NM_052980 5´-TCT-CTT-TCC-CGT-CGC-TCT-TG-3´ 
CAR (Nr3i2) 5'-TGG-TCC-CAT-CTG-TCC-GTT-TG-3' 209 bp NM_022941.3 5'-GCT-CTT-TCT-GCT-GCT-GAC-TC-3' 
PGR (Nr3c3) 5´-CGA-TGG-AAG-GGC-AGC-ATA-AC-3´ 286 bp NM_022847 5´-TTG-ATG-AGT-GGC-GGA-ACC-AG-3´ 
MR (Nr3c2) 5´-GGC-TTC-TGG-GTG-TCA-CTA-TG-3´ 147 bp NM_013131.1 5´-CAG-GCA-GGA-CAG-TTC-TTT-CG-3´ 
AR (Nr3c4) 5'-CTG-CCT-GAT-CTG-TGG-AGA-TG-3' 181 bp NM 012502.1 5'-TTT-CCG-GAG-ACG-ACA-CGA-TG-3' 
Cyp1a1 5'-ATT-TGA-GAA-GGG-CCA-CAT-CC-3' 178 bp NM_012540.2 5'-CAT-GAG-GCT-CCA-AGA-GAT-AG-3' 
Cyp2b1 5'-TTC-TGC-GCA-TGG-AGA-AGG-AG-3' 223 bp NM_001134844.1 5'-TGG-GAT-ACA-CCT-CAG-TGT-TC-3' 
Cyp2c12 5'-GGA-GAG-CCA-CAA-GAC-ATT-TC-3' 107 bp NM_031572.1 5'-TTC-CAT-CAC-TAG-CCA-CTC-TG-3' 
Cyp4a1 5'-CTT-TGG-GCA-CAA-GCA-GTT-TC-3' 171 bp NM_153307.1 5'-TTG-GCC-TTT-GGA-TCT-GAT-CG-3' 
Beta Actin  5´-ATG-TTG-CCC-TAG-ACT-TCG-AG-3´ 175 bp NM_031144.2 5´-TCA-TGG-ATG-CCA-CAG-GAT-TC-3´ 
 
3.8.5 Agarose gel electrophoresis 
The amplified DNA fragments resulted from PCR (see section 0) were separated by using 
1.2% agarose gels and visualized under UV-light by EtBr staining. For that purpose 0.96 g 
agarose was dissolved in 80 ml 1x TBE. The mixture was heated in a microwave until the 
agarose was completely melted. After a short cool down of the mixture, 6 µl ethidium 
bromide were added and the gel was poured in the gel sleigh containing a comb. Following 
the polymerization step of approximately 40 minutes, the comb was removed and 10 µl of the 
PCR product and 5 µl of the 50 bp marker were loaded on the gel. 1x TBE was used as 
electrophoresis buffer and the gel ran about 35 minutes at 125 V. Finally the bands were 
visualized through a UV-light GelDoc 2000. 
 
3.8.6 Quantitative real time-PCR (qrt-PCR) 
As a first step the 1x MM (Table 7) was prepared without adding the template and mixed 
well. For the reaction 21 µl MM were added to 4 µl of the appropriate cDNA in a 0.5 ml 
reaction tube.  
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Table 7: Master mix for qrt-PCR. 
Reagent Volume per sample (x2 for duplicates) 
TaqMan® gene expression assays 0.625 µl 
2x TaqMan® Gene Expression MM 6.250 µl 
DEPC H2O 3.625 µl 
cDNA template 2.000 µl 
Total volume 12.500 µl 
 
For duplicates (2 wells per sample), 12 µl per well were transferred to the MicroAmp Fast 
Optical 96-well reaction plate (Applied Biosystems). The plate was closed with a MicroAmp 
Optical Adhesive Film (Applied Biosystems) and put into an ABI Prism 7500 Real-Time PCR 
apparatus (Applied Biosystems). The qrt-PCR cycling program shown in table 8 was used.  
 
Table 8: qrt-PCR cycling program. 
Step Temperature Time 
1x 50°C 2 min  
1x 95°C 10 min  
40-50x 95°C 
60°C 
15 sec 
1 min 
dissociation control (1x) 95°C 
60°C 
95°C 
15 sec 
1 min 
15 sec 
 
The CT values for each sample were averaged and this value was used in subsequent 
calculations. ß2-Microglobulin was chosen as the housekeeping gene Relative gene 
expression was determined following the ∆∆Ct-method. Table 9 summarizes the used 
TaqMan® gene expression assays (Applied Biosystems). 
 
Table 9: qrt-PCR probes (TaqMan® Gene Expression Assays). 
TaqMan® Gene Expression Assays Assay ID 
iNOS Rn00561646_m1 
COX-2 Rn00483828_m1 
TNFα Rn99999017_m1 
IL-6 Rn99999011_m1 
CAR (Nr1i3) Rn00576085_m1 
PXR (Nr1i2) Rn00583887_m1 
PPARα  Rn00566193_m1 
β2-Microglobulin Rn00560865_m1 
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3.8.7 Microarray analysis 
All Gene Chip experiments were done with in vivo treated rats as indicated in chapter 3.4. 
Liver perfusion and cell separation were done as described in chapters 3.5 and 3.6 with the 
only exception that before liver perfusion one small liver lobe was ligated and frozen in liquid 
nitrogen until further usage.   
 
Total RNA isolation: 
HC cell pellets with a cell number of 2 x 106 cells and NPC cell pellets with a cell number of 
15 x 106 were produced. Afterwards the cell pellets were disrupted by adding 700 µl QIAzol 
Lysis Reagent and homogenized through a QIAshredder (centrifugation at full speed for 2 
minutes). RNA isolation was done by using the Qiagen miRNeasy Mini Kit according to 
manufactures instructions. For the long-term PB in vivo study Qiagen RNeasy Lysis Buffer 
(RLT buffer) was used and RNA isolation was done by using the Qiagen RNeasy Plus Mini 
Kit according to manufactures instructions. 
 
RNA quality testing: 
As a pre-quality test RNA was separated on an agarose gel to check the degradation level of 
the RNA. Therefore a 1.5% agarose gel was prepared as described in section 3.8.5. To 1µl 
RNA sample, 1 µl 6x loading dye and 4 µl DEPC H2O was added. The total volume of 6 µl 
was loaded on the gel and run 25 minutes at 80 V. The quality of the 28S and 18S rRNA was 
checked by visualization of the characteristic bands under UV-light. 
 
The not degraded RNA was used for measuring the RNA Integrity number (RIN) with an 
Agilent 2100 Bioanalyzer according to manufactures instructions. 
 
Processing of Gene Chip® experiments: 
An appropriate amount of each RNA sample from the in vivo studies (treated vs. controls) 
was used for Gene Chip analysis with the Affymetrix Rat Genome 230 2.0 Array (Affymetrix). 
All Gene Chip® experiments were kindly done in cooperation with Priv. Doz. Mag. Dr. Martin 
Bilban of the institution “Core Faciltiy Genomics” of the MUW.  
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3.9 Methods on DNA-level 
3.9.1 Autoradiography 
Primary hepatocytes were cultured in (35 x 10 mm) petri dishes. DNA-replication was 
determined by labelling new synthesized DNA with 3H-thymidine and subsequent 
autoradiography. Therefore 3H-thymidine was added to medium with a concentration of 1.0 
µCi/ml 24 hours before fixing of the cells. For harvesting, the cells were washed twice with 
0.9% NaCl solution. Afterwards the cells were fixed with 1 ml per well of 4% buffered formalin 
according to Lillie for 90 minutes at 4°C. Finally the fixed cells were washed three times with 
0.9% NaCl and stored at 4°C in sterile distilled H 2O. Autoradiography served to determine 
the percentage of nuclei with incorporated 3H-thymidine. Autoradiography was kindly 
performed by the technical assistants Birgit Mir-Karner, Krystyna Bukowska and Helga 
Koudelka. 
 
3.10 Methods on protein level 
3.10.1 Isolation of proteins from cells 
Protein isolation from primary liver cells was performed at different time points and always on 
ice for a stable detection of protein phosphorylation. As a first step, the medium was 
removed and the cells were washed once with ice cold 1x PBS. Afterwards cells of 2-3 wells 
were lysed with 75 µl RIPA buffer and pooled together for one protein sample. Finally protein 
samples were homogenized by ultrasonic (Bandelin Sonopuls HD2070) and centrifuged at 
14,000 rpm for 5 minutes at 4 °C. The samples were stored at -20°C until further usage. 
 
3.10.2 Isolation of proteins from tissue 
The appropriate amount of Precellys 1.4 mm ceramic beads (Peqlab, Erlangen, Germany) 
was transferred in isolation tubes (Peqlab, Erlangen, Germany) and 300 µl RIPA buffer was 
added on ice. The liquid nitrogen frozen tissue was cut with a scalpel in approximately 50 mg 
pieces, the weight was noted and the tissue was put with a forceps into the isolation tubes. 
The tissue was homogenized in with a Precellys® 24 (Peqlab, Erlangen, Germany) for 2 x 15 
seconds at 6,000 x g. Afterwards the samples were incubated for 30 minutes on ice and 
centrifuged at 10,000 x g for 10 minutes at 4°C. Th e supernatant was transferred into a new 
tube and centrifuged again at 10,000 x g for 10 minutes at 4°C. Finally the gained 
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supernatant was used as a total cell lysate for determination of protein concentration and 
further protein analyses. The protein samples were stored at -80°C.  
 
3.10.3 Determination of protein concentrations 
Protein concentration was measured with the Bradford method in a 96-well plate. A standard 
row with increasing BSA concentrations (ranging from 0-6 µg/µl) was pipetted to get a 
calibration curve. 1 µl sample was diluted with 9 µl distilled H2O and pipetted in duplicates 
into the 96-well plate. The Bradford protein assay kit (Biorad) was diluted 1:5 and 100 µl of 
the dilution were added to each well. The absorbance was measured with a microplate 
reader (Tecan Infinite® 200 PRO) at a primary wavelength of 595 nm. 
 
3.10.4 Western blot  
SDS-Page: 
Firstly, the proteins were separated according to their size and charge on a 12% SDS-Page. 
The SDS-Polyacrylamide gel consists of two different gels which were prepared from the 
components listed in table 10.  
 
Table 10: Composition of the SDS-PAGE. 
12% Resolving Gel 4% Stacking Gel 
Component Volume in ml (for 2 gels) Component 
Volume in ml 
(for 2 gels) 
40% Acrylamide 3.600 40% Acrylamide 0.500  
1,5 M Tris pH 8.8 3.000 1 M Tris pH 6.8 0.625 
10% SDS 0.120 10% SDS 0.050 
Distilled H2O 5.200 Distilled H2O 3.800 
10% APS 0.060 10% APS 0.025 
TEMED 0.006 TEMED 0.005 
 
As a next step, a specific volume of the protein lysates was filled up with RIPA buffer to 
reach the same concentration and sample volume. Generally between 5 µg and 20 µg 
protein were loaded on the gel. Than one fifth of the sample volume 5x Laemmli loading 
buffer was added and the samples were heated for 5 minutes at 95°C. Finally 5 µl protein 
ladder and the whole sample volume were loaded on the gel. Laemmli buffer was used as 
electrophoresis buffer. Electrophoresis of the proteins was done at 60V until the proteins 
reached the end of the stacking gel (after approximately 30 minutes) and was going on at 
125 V for about 1 hour in the resolving gel. 
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Blotting: 
To transfer the proteins from the gel on a PVDF membrane (GE-Healthcare) the tank-blot 
system with 1x transfer buffer was used. The transfer was done on ice at 30V overnight. To 
assure that the transfer worked stable, the proteins on the membranes were stained with 
Ponceau S. The staining was washed out with distilled H2O and the blots were dried and 
stored at 4°C until further usage. 
 
Blocking: 
The dried blots were reactivated with methanol and shortly washed with distilled H2O. 
Blocking was done with TBST and 3% BSA for approximately 1 hour at room temperature. 
 
Immunodetection: 
After blocking, the blots were incubated with the primary antibody (Table 11) over night at 
4°C. On the next day, the blots were washed three t imes in TBST and incubated with 
horseradish peroxidase conjugated secondary antibodies (Table 11) for 1-2 hours at room 
temperature.  
Table 11: Antibodies used for immunodetection. 
Primary Antibodies Secondary Antibodies 
Antibody Dilution Antibody Dilution 
pERK-anti-mouse 
(Sigma) 
1:10000 in TBST  
and 3% BSA 
Goat-anti-mouse 
(Dako) 
1:10000 in TBST  
and 3% BSA 
ERK-anti-rabbit 
(Sigma) 
1:1000 in TBST 
and 2% BSA 
Goat-anti-rabbit 
(Biorad) 
1:10000 in TBST  
and 2% BSA 
 
 
The blots were washed again three times in TBST and afterwards they were developed with 
the Amersham ECL plus kit (GE-Healthcare). Chemiluminiscence was detected by using a 
Hyperfilm ECL (Thermo Scientific, Waltham, MA) on an x-ray machine. Signal intensities 
were quantified with ImageQuant™ (GE-Healthcare). After the development of the x-ray 
films, the blots were shortly washed in TBST and dried for storage or incubated with the next 
primary antibody. 
 
3.10.5 Enzyme-linked immunosorbent assay (ELISA) 
TNFα was detected in supernatants of HC and NPC at different time points. The rat TNFα 
Module Set (Bender MedSystems) was applied according to manufacturers’ instructions. 
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4. Results 
4.1 Gene expression pattern of CYP in liver cell types 
4.1.1 Basal mRNA level of CYP in untreated primary liver cells 
First the basal mRNA levels of specific CYP in different types of untreated primary liver cells 
were determined. Due to prior results from literature research  (Carver, 2007; Denison, et al., 
1995), the expression patterns of Cyp1a1, Cyp2b1, Cyp2b2, Cyp2c12 and Cyp4a1 were 
studied. Therefore specific primers were designed and used to amplify cDNA from untreated 
HC, EC and KC (Figure 6). 
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Figure 6: Basal mRNA levels of specific CYP in untreated liver cell types. 
HC, KC and EC were isolated from untreated rats and were kept in culture for 24 hours. The cells were harvested, 
RNA was isolated and cDNA was generated. The cDNA was used as template for PCR amplification. After 40 
amplification cycles, products were loaded on a 1.2% agarose gel, stained with EtBr and visualized with UV-light. 
ß-actin was used as a positive control and reference gene. Volumes of the PCR products were determined by 
densitometry (Quantity One 4.2.1; Bio-Rad Laboratories, USA). The amount of data obtained for the gene of 
interest was normalized by β-actin (=fold ß-actin). The data are means +/- SEM of two independent experiments. 
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At all, HC showed the highest mRNA levels of Cyp1a1, Cyp2b1 and Cyp2b12. In EC, 
Cyp2b2 showed the maximal mRNA level. Cyp2b1 and Cyp2b2 expressions were not found 
in KC and transcripts of Cyp4a1 were not detectable in any cell type examined. This 
indicates that the basal mRNA levels of the selected CYP feature a cell type specific 
expression pattern and are generally low in the mesenchymal liver cell types. 
 
4.1.2 mRNA level of CYP in treated primary liver cells 
In order to determine whether the various liver cell types are able to respond to NGC, they 
were treated with CPA or PB and the mRNA levels of different CYP were examined. 
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Figure 7: CYP expression induced in liver cell types by treatment with CPA or PB. 
HC, KC and EC were isolated from untreated rats and were kept in culture. After two hours in culture, the cells 
were treated with CPA or PB as follows: CPA was dissolved in DMSO and added to medium at a final 
concentration of 10 µM. The cells treated with 0.2% DMSO served as control for CPA. PB was dissolved in 
medium and applied at a final concentration of 1 mM. Untreated cells served as control for PB. 24 hours later, 
cells were harvested, RNA was isolated and cDNA was generated. The cDNA was used as template for PCR 
amplification. After 39 amplification cycles, products were loaded on a 1.2% agarose gel, stained with EtBr and 
visualized with UV-light. ß-actin was used as a positive control and reference gene. Volumes of the PCR products 
were determined by densitometry (Quantity One 4.2.1; Bio-Rad Laboratories, USA). The amount of data obtained 
for the gene of interest was normalized by β-actin (=fold ß-actin). The data derive from one experiment. 
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Figure 7 shows that CPA treatment increased the expression of Cyp1a1 and Cyp2c12 in HC 
when compared to DMSO. PB treatment of HC increased the mRNA level of Cyp2b1 and 
significantly induced transcription of Cyp2c12 when compared to the untreated control. 
 
The expression level of Cyp1a1, Cyp2b1 and Cyp2c12 were slightly elevated or induced in 
CPA treated KC. PB treatment induced transcription of Cyp1a1 to a small extent in KC. Apart 
from that treatment with PB showed no great effect on the specific CYP transcripts in KC. 
 
In CPA treated EC, Cyp2c12 showed a slight increase in gene expression. There was an 
increase of Cyp1a1 and induction of Cyp2c12 mRNA when EC were treated with PB. 
Expression of Cyp2b1 could not be measured in treated and untreated EC after 39 cycles of 
PCR. 
 
In summary, NGC treatment of primary liver cells lead to a response in mRNA levels of 
specific CYP, most of all in HC and EC. Cyp1a1 and Cyp2c12 could serve as a 
transcriptional positive control for the CPA effect in HC. The PB effect could be confirmed by 
measuring an elevated Cyp2b1 and Cyp2c12 expression in HC. 
 
4.2 Gene expression pattern of NR 
4.2.1 Basal mRNA level of NR in untreated primary liver cell types 
At first, it was checked if several NR are expressed in untreated HC, KC and EC. For this 
purpose, the mRNA levels of the receptors PXR, CAR, PGR, ERα, ERβ and PPARα were 
determined. The specific primers for the appropriate genes were designed and used to 
amplify cDNA from untreated HC, EC and KC. Figure 8 shows whether a basal expression of 
the appropriate NR could be determined with PCR or not. Additionally, it was investigated 
whether the culture time influences the mRNA levels of NR in primary liver cells.  
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Figure 8: Basal mRNA level of NR in untreated liver cell types in dependence of PCR cycle numbers. 
HC, KC and EC were isolated from untreated rats and were kept in culture for 6 hours or 24 hours. The cells were 
harvested, RNA was isolated and cDNA was generated. The cDNA was used as template for PCR amplification. 
After 33, 36, 39 and 42 amplification cycles, products were loaded on a 1.2% agarose gel, stained with EtBr and 
visualized with UV-light. ß-actin was used as a positive control and reference gene. Volumes of the PCR products 
were determined by densitometry (Quantity One 4.2.1; Bio-Rad Laboratories, USA). The amount of data obtained 
for the gene of interest was normalized by β-actin (=fold ß-actin). The data derive from one experiment.  
 
In general, HC are best equipped with the tested NR, only the hormone-specific NR ERβ and 
PGR were not detectable. Especially, PPARα shows the highest expression in HC which 
were kept in culture for 6 hours or 24 hours. In untreated KC a slight expression of CAR and 
PPARα was detectable. Expression of PXR and PGR could just be measured upon cycle 42 
in KC. Among NR tested in EC, the highest mRNA levels were found for CAR followed by 
PXR whereas PPARα, PGR and ERα were only detectable upon cycle 42. Additionally, a 
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ERα 
PGR 
ERβ 
small influence of the culture time could be observed as the primary liver cells which were in 
culture for 24 hours show a higher basal expression level compared to the primary liver cells 
which were in culture for 6 hours.  
 
As the hormone-specific NR PGR and ERα show very low mRNA levels and ERβ could not 
be detected in any cell type of the rat liver, it was important to check if the primers designed 
work without failure. For this purpose, cDNA isolated from highly hormone dependent rat 
organs, i.e. uterus, ovary and kidney was amplified with these primers. As estimated PGR, 
ERα and ERβ are strongly expressed in uterus, ovary and kidney of rats (Figure 9). This 
indicates that the designed primer work specifically and that the results obtained from 
primary liver cells appear to be reliable. 
 
 
 
 
 
 
 
 
 
Figure 9: mRNA level of hormone-specific NR in rat uterus, ovary and kidney. 
The cDNA obtained from tissue or cells of rat uterus, ovary and kidney were used as template for PCR 
amplification. After 40 amplification cycles products were loaded on a 1.2% agarose gel, stained with EtBr and 
visualized with UV-light. For details see section 3.8.4 and 3.8.5 of materials and methods. 
 
4.2.2 mRNA level of specific NR in treated primary liver cell types 
Previous studies have shown that NGC can influence gene expression of specific NR. 
(Zhang, et al., 1999; Moreau, et al., 2007; Gonzalez, et al., 2008; Couse, et al., 1999) For 
this thesis, it was checked whether NGC induce NR in the different liver cell types (Figure 
10).  
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Figure 10: NGC induce mRNA level of specific NR in different liver cell types. 
HC, KC and EC were isolated from untreated rats and were kept in culture. After two hours in culture, the cells 
were treated with CPA, WY or PB as follows: CPA was dissolved in DMSO and added to medium at a final 
concentration of 10 µM. The cells treated with 0.2% DMSO served as control for CPA. WY was dissolved in 
DMSO and added to medium at a final concentration of 20 µM. The cells treated with 0.2% DMSO served as 
control. PB was dissolved in medium and applied at a final concentration of 1 mM. The untreated cells served as 
control for PB. 24 hours later, the cells were harvested, RNA was isolated and cDNA was generated. The cDNA 
was used as template for PCR amplification. After 35 amplification cycles (for HC) and 40 amplification cycles (for 
KC and EC) products were loaded on a 1.2% agarose gel, stained with EtBr and visualized with UV-light. ß-actin 
was used as a positive control and reference gene. Volumes of the PCR products were determined by 
densitometry (Quantity One 4.2.1; Bio-Rad Laboratories, USA). The amount of data obtained for the gene of 
interest was normalized by their specific controls (DMSO or medium). The data are means +/- SEM of two 
independent experiments. 
 
When HC were treated with CPA for 24 hours, the expression level of ERα decreased by half 
compared to the control. Treatment of CPA had no significant effect on ERα in EC and failed 
to induce expression of the hormone receptor in KC. When HC were treated with WY, no 
change in mRNA level of PPARα could be observed. Treatment of EC with WY resulted in a 
threefold increase in the expression of PPARα. PPARα remained undetectable in KC. The 
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mRNA level of CAR showed on the one side an increase in KC and EC but on the other side 
a decrease in HC when the cells were treated with PB. Treatment of HC and EC with PB 
reduced the expression level PXR.  
 
Overall, the results obtained with standard PCR show large deviations in mRNA levels. In HC 
NR transcripts tend to decrease after treatment with NGC while the opposite occurs in EC. 
Almost no effect was observable in KC. The next step was to verify the data by applying qrt-
PCR. 
 
4.2.3 qrt-PCR analyses of NR in treated and untreated primary liver cell types 
Next, the expression levels of CAR, PXR and PPARα was quantified by qrt-PCR in HC, KC 
and EC. Furthermore, it was checked whether treatment with CPA, PB or WY changes 
mRNA levels of these NR in primary liver cell types (Figure 11). 
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Figure 11: Variable expression of NR in treated and untreated liver cell types. 
HC, KC and EC were isolated from untreated rats and were kept in culture. After two hours in culture, the cells 
were treated with CPA, WY or PB as follows: CPA was dissolved in DMSO and added to medium at a final 
concentration of 10 µM. The cells treated with 0.2% DMSO served as control for CPA. WY was dissolved in 
DMSO and added to medium at a final concentration of 20 µM. The cells treated with 0.2% DMSO served as 
control. PB was dissolved in medium and applied at a final concentration of 1 mM. The untreated cells served as 
control for PB. 24 hours later, the cells were harvested, RNA was isolated and cDNA was generated. The cDNA 
was used as template for qrt-PCR. The ABI-Prism PCR standard protocol was used on an ABI-Prism/7500 
Sequence Detection System with TaqMan-based assays. The mRNA levels were quantified with an ABI-
Prism/7500 SDS-software and normalized to ß2-M. The expression level of treated cells was related to the 
expression level of their controls. The data are means +/- SEM of three independent experiments.  
 
Expression patterns of CAR 
General expression of CAR was detectable to a low extent in untreated HC and EC. 
Treatment with CPA did not change mRNA level in HC and reduced mRNA level in EC when 
compared to the control. When EC were treated with PB, a 2-fold increase in gene 
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expression of CAR was detectable. In contrast to the standard PCR method (Figure 10), 
CAR was not detectable with qrt-PCR in KC which were treated with PB.   
 
Expression patterns of PXR 
Expression of PXR was detectable in all three liver cell types with HC showing the highest 
mRNA level, followed by EC and KC. Treatment with CPA did not change mRNA level in HC 
and strongly reduced mRNA level in EC when compared to the control. In KC, treatment with 
CPA slightly increased gene expression of PXR. Treatment of liver cells with PB showed 
almost the same effect on PXR expression as already demonstrated with the previous 
standard PCR experiment (Figure 10). 
 
Expression patterns of PPARα 
PPARα is detectable in untreated HC and EC and undetectable in KC. Similar to the 
preceding standard PCR experiment, the expression of PPARα was slightly elevated when 
EC were treated with WY.  
 
Overall, the results obtained with qrt-PCR confirm more or less the data generated with 
conventional PCR, i.e. both approaches showed rather similar expression patterns in primary 
liver cell types with the exception of KC. Here, CAR could not be detected via qrt-PCR when 
KC were treated with PB. It is difficult to find reasons for this mismatch but an explanation 
could be the different primers used in conventional PCR and qrt-PCR or reduction in cDNA 
quality over time. 
 
4.2.4 Specific inhibitors for PXR and CAR 
Specific inhibitors for PXR and CAR were applied in order to find out whether CPA exerts its 
effect over these NR. Previous studies demonstrated that sulforaphane (SFN), found 
abundantly in broccoli, blocks xenobiotic-mediated activation of human PXR (Zhou, et al., 
2007). Another research group identified 1-(2-chlorophenylmethylpropyl)-3-isoquinoline-
carboxamide (PK-11195) as a selective and potent inhibitor of human CAR (Li, et al., 2008). 
Here, HC were treated simultaneously with the NGC CPA and the inhibitors of PXR and/or 
CAR. On the one hand, it was important to check the effect of the antagonists on mRNA 
levels of CAR and PXR (Figure 12). On the other hand, it was investigated whether the 
specific inhibitors block the CPA-induced DNA synthesis in HC (Figure 13).  
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Figure 12: Effect of antagonists of CAR and PXR on mRNA level in HC. 
HC were isolated from untreated rats and were kept in culture. After two hours in culture, the cells were treated 
with CPA and the respective inhibitor as follows: CPA was dissolved in DMSO and added to medium at a final 
concentration of 10 µM. The PXR inhibitor SFN and the CAR inhibitor PK-11195 were added at a final 
concentration of 10 µM respectively. The cells treated with 0.2% DMSO served as control. 24 hours later, the cells 
were harvested, RNA was isolated and cDNA was generated. The cDNA was used as template for qRT-PCR. 
The ABI-Prism PCR standard protocol was used on an ABI-Prism/7500 Sequence Detection System with 
TaqMan-based assays. The mRNA levels were quantified with an ABI-Prism/7500 SDS-software and normalized 
to ß2-M. The expression level of treated cells was related to the expression level of DMSO treated cells (=fold 
control DMSO). The data derive from one experiment. 
 
The results of this experiment demonstrate that CPA reduced the expression levels of CAR 
and PXR and that the specific inhibitors SFN and PK-11195 failed to show inhibitory effects 
on mRNA level of CAR and PXR in rat HC. However, CPA is known to stimulate DNA 
replication in HC (Löw-Baselli, et al., 2000). Thus it was the next step to find out whether the 
inhibitors are capable of interfering with the DNA synthesis induction by CPA. 
 
 
  
 
53 
 
GSTp-neg HC
CO
DM
SO CP
A
CP
A +
 
SF
N
CP
A +
 
PK
-
11
19
5
0.0
0.5
1.0
1.5
D
N
A 
re
pl
ic
at
io
n
 
(%
 
LI
)
 
Figure 13:Effect of CAR/PXR-antagonists on DNA replication of HC treated with or without CPA. 
HC were isolated from untreated rats and were kept in culture. The inhibitors were added 2 hours after seeding. 
Treatment was renewed with a medium change 24 hours after seeding. Applied concentrations: PXR inhibitor 
SFN 25 µM; CAR inhibitor PK-11195 10 µM; CPA 10 µM. Untreated cells and cells treated with 0.2% DMSO 
served as controls. 3H-thymidine was added 24 hours before harvesting of cells. 72 hours after seeding cultures 
were fixed and subjected to autoradiography. The nuclei with incorporated 3H-thymidin were counted and the 
percentages were calculated. In each experiment 1000 nuclei of HC were scored. The data are means +/- SEM 
from independent experiments on 2 rats. 
 
The application of CPA strongly increased DNA replication in GSTp-neg cells when 
compared to the untreated or DMSO treated cells. The PXR inhibitor SFN was able block the 
induction of DNA replication in HC whereas the CAR inhibitor PK-11195 had no effect. 
Taking these results together, CPA seems to exert its effect on DNA replication of HC via 
PXR.  
 
4.3 Gene expression pattern of specific pro-inflammatory factors 
The connection between hepatocarcinogenesis and inflammation is confirmed. Many 
previous studies with specific mouse models found important key factors such as TNFα or IL-
6 which link these two processes. (Berasain, et al., 2009) Furthermore, microarray analysis 
(Data not shown) revealed that HC, isolated from PB-exposed livers, tended to counter-react 
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in order to cope with the action of the pro-inflammatory chemo-/cytokines and to survive in a 
stressed mesenchyme. The increased production of TNFα by NPC leaves a clear signature 
in HC consisting of deregulations and counter-regulations within the TNFα-, interferon-, and 
NFκB-driven pathways. This raises the question whether NPC secrete soluble factors which 
changes the mRNA level of pro-inflammatory genes in hepatocytes or vice versa. Thus the 
experiment includes the in vivo part where male Wistar rats were treated for 24 hours or for 
two weeks with PB (see section 3.4). Subsequently, one cell type was treated with the 
supernatant of the other cell type (see section 3.7.2). For a better understanding the 
experimental design is shown in figure 14. 
 
 
Figure 14: Experimental design of the supernatant experiment. 
Male Wistar rats were treated either for 24 hours with a single dose of PB by gavage or for 14 days with PB 
through their drinking water. Untreated rats served as control. The livers were perfused and cells were separated 
in HC and NPC and were kept in culture. The HC, obtained from the untreated rats were treated with the 
supernatant of the NPC, obtained from the PB treated or untreated rats. The NPC, obtained from the untreated 
rats were treated with the supernatant of the HC, obtained from the PB treated or untreated rats. After 24 hours 
treatment, the cells were harvested for mRNA isolation. The mRNA levels of the pro-inflammatory genes of 
interest were determined via qrt-PCR. 
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4.3.1 Supernatant effects of isolated liver cell types 
The following two graphs outline the influence of PB treatment in vivo on the secretome of 
isolated liver cell types. 
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Figure 15: Effect of one day PB treatment in vivo on the secretome of isolated liver cell types. 
Male Wistar rats were treated with a single dose of PB administered by gavage. The livers were perfused; cells 
were separated in HC and NPC and kept in culture. After 24 hours  HC and NPC of untreated rats were treated 
with the various supernatants as follows: In (A) HC were treated with two different supernatants of NPC (NPC-PB 
supernatant, NPC-CO supernatant) or just with RPMI as control. In (B) NPC were treated with two different 
supernatants of HC (HC-PB supernatant, HC-CO supernatant) or just with RPMI as control. 24 hours later, the 
cells were harvested, mRNA was isolated and cDNA was generated. The cDNA was used as template for qrt-
PCR. The ABI-Prism PCR standard protocol was used on an ABI-Prism/7500 Sequence Detection System with 
TaqMan-based assays. The mRNA levels were quantified with an ABI-Prism/7500 SDS-software and normalized 
to ß2-M. The expression level of treated cells was related to the expression level of RPMI treated cells (=fold 
control). The data are means +/- SEM of ≥ two independent experiments (Figure 15:A) or ≥ three experiments 
(Figure 15:B). 
 
Treatment of HC with NPC-CO supernatant induced the mRNA level of pro-inflammatory 
genes, i.e. COX-2 and iNOS expression were 10- and 40-fold elevated, respectively (Figure 
15A). This effect became enhanced when the secretome of NPC, which had been isolated 
from a PB-treated rat, was used. An 80-fold upregulated iNOS mRNA level was observable 
when compared to HC kept in pure medium only (Figure 15A). 
 
In contrast, the supernatant of PB-treated HC reduced the expression of pro-inflammatory 
genes in NPC (Figure 15B). This indicates that HC counteract the pro-inflammatory action of 
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the PB-activated mesenchyme. Thus PB induces a pro-inflammatory state in the 
mesenchyme. 
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Figure 16: Effect of 14 days PB treatment in vivo on the secretome of isolated liver cell types. 
Male Wistar rats were treated with PB for 14 days via drinking water. The livers were perfused; cells were 
separated in HC and NPC and kept in culture. After 24 hours, HC and NPC of untreated rats were treated with the 
various supernatants as follows: In (A) HC were treated with two different supernatants of NPC (NPC-PB 
supernatant, NPC-CO supernatant) or just with medium RPMI as control. In (B) NPC were treated with two 
different supernatants of HC (HC-PB supernatant, HC-CO supernatant) or just with medium RPMI as control. 24 
hours later, the cells were harvested, mRNA was isolated and cDNA was generated. The cDNA was used as 
template for qrt-PCR. The ABI-Prism PCR standard protocol was used on an ABI-Prism/7500 Sequence 
Detection System with TaqMan-based assays. The mRNA levels were quantified with an ABI-Prism/7500 SDS-
software and normalized to ß2-M. The expression level of treated cells was related to the expression level of 
RPMI treated cells (=fold control). The data are means +/-SEM of ≥ two independent experiments.  
 
Also after 14 days treatment in vivo, there was a strong effect of the NPC-PB supernatant on 
HC (from untreated rats) compared to the effect of the NPC-CO supernatant (Figure 16A). All 
target genes were strongly elevated such as TNFα showing a 37-fold upregulation in HC. 
Also slight effects of the HC-PB supernatant on NPC could be observed (Figure 16B) when 
compared to HC-CO supernatant, e.g. 0.5 downregulation of TNFα. 
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4.4 Analysis of TNFα as pro-inflammatory factor 
4.4.1 Treatment of primary liver cells with recombinant TNFα 
Considering the findings of the supernatant experiments (chapter 4.3), it was essential to find 
the factors which lead to the pro-inflammatory effect of the PB-NPC supernatant on HC. The 
question was whether TNFα may cause this effect. Primary liver cells were treated with the 
recombinant form of TNFα and mRNA levels of TNFα, COX-2, iNOS and IL-6 were 
determined (Figure 17).  
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Figure 17: Effect of treatment with recombinant TNFα on primary liver cells. 
The livers of untreated rats were perfused and cells were separated into HC and NPC and were kept in culture. 
After two hours, the cells were treated with 1 ng and/or 10 ng recombinant TNFα. 24 hours later, the cells were 
harvested, mRNA was isolated and cDNA was generated. The cDNA was used as template for qrt-PCR. The ABI-
Prism PCR standard protocol was used on an ABI-Prism/7500 Sequence Detection System with TaqMan-based 
assays. The mRNA levels were quantified with an ABI-Prism/7500 SDS-software and normalized to ß2-M. The 
expression level of treated cells was related to the expression level of untreated cells (=fold medium). The data 
are means +/- SEM of two independent experiments. 
 
As expected, a strong increase in expression of TNFα and iNOS was detectable in HC which 
were treated with recombinant TNFα. Furthermore, mRNA levels of COX-2 and IL-6 were 
inducible by the recombinant protein. In comparison to the medium controls, no significant 
changes of the mRNA level in NPC were detectable.  
 
Taking these results together, the cytokine TNFα has a strong effect on HC and may belong 
to one of the factors which led to the effects of the supernatant experiment (see section 
4.3.1). 
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4.4.2 TNFα release 
Moreover, it was tried to determine the amount of released TNFα in the secretome of primary 
liver cells. Therefore the supernatants of HC and NPC, from rats treated with PB for 14 days 
as well as from control rats, were taken at different time-points and the concentration of 
released TNFα was measured via ELISA (Figure 18).  
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Figure 18: Effect of 14 days PB in vivo treatment on TNFα release of liver cell types. 
Male Wistar rats were treated with PB for 14 days via drinking water. The livers were perfused; cells were 
separated in HC and NPC and kept in culture. The supernatants were collected 1h, 3h and 6h after seeding and 
concentration of TNFα was determined with ELISA. The data are means of two independent experiments. 
Detection limit of rat TNFα ELISA is 14 pg/ml according to manufacturer (indicated as dotted grey line). 
 
In general, the concentration of TNFα in the supernatant of primary liver cells was very low or 
below the detection limit of the used ELISA (detection limit = 14 pg/ml). The highest 
concentration of secreted TNFα was found in supernatants of NPC controls after 6 hours in 
culture (Figure 18). TNFα was not detectable in HC-PB supernatants at all. In general, these 
results revealed that TNFα could not serve as the solitary factor which is responsible for the 
upregulated pro-inflammatory genes in HC from the supernatant experiment (see section 
4.3.1). 
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4.5 DNA Chip analysis of the 24 hours CPA in vivo treatment 
4.5.1 Overview of regulated genes 
In vivo treatment of female rats with a single dose of CPA (100 mg/kg body weight) for 24 
hours resulted in a wide range of differently expressed genes and altered pathways such as 
the ERK pathway. In HC more than 500 genes were downregulated and more than 740 
genes were upregulated. In NPC, the treatment with CPA caused a downregulation of more 
than 90 genes and an upregulation of more than 450 genes. The following paragraphs show 
just a small part of the results from the DNA Chip analysis.  
 
4.5.2 Influence of CPA in vivo treatment on CYP 
Downregulated CYP (Figure 19A) 
Cyp1a2 expression was reduced by half in HC due to CPA treatment. Cyp2c23 and Cyp4a1, 
which are generally involved in arachidonic acid metabolism, showed a 50% decrease in HC. 
Additionally, the steroid hydroxylase Cyp17a1 was downregulated in HC derived from rats 
which were treated with CPA. In NPC, the CYP26 enzymes with retinoic acid 4-hydroxylase 
activity showed a 50-80% diminution of their expression levels.  
 
Upregulated CYP (Figure 19B) 
It is well known that PB strongly increases Cyp2b1 expression level in primary rat liver cells  
(Denison, et al., 1995) but in that case CPA also increased Cyp2b1 expression up to 10-fold 
in NPC and HC after in vivo treatment with CPA. Cyp2c22 is a retinoic acid-metabolizing 
enzyme in rat liver and was approximately 2.5-fold in HC and more than 14-fold upregulated 
in NPC. Many steroids and xenobiotics are able to increase Cyp3a1 mRNA level in rat liver 
and here CPA increased gene expression level of Cyp3a1 in HC more than 2-fold and in 
NPC almost 20-fold.  
 
At all, it is striking that Cyp2b1, Cyp2c22 and Cyp3a1 are upregulated in parenchymal and 
mesenchymal cells as a cause of in vivo treatment with CPA. Thus, these three enzymes 
may play important roles in CPA metabolism of both cell types. Additionally, mRNA analysis 
of in vitro treated cells shows different results (see section 4.1.2). As opposed to this (Figure 
7), here CYP1a1 and Cyp2c12 mRNA level were not found to be changed. 
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Figure 19: Effect of in vivo treatment with CPA on mRNA level of CYP genes in liver cell types. 
Female Wistar rats, 8-12 weeks old, were treated with a single dose of CPA (100 mg/kg body weight dissolved in 
corn oil) by gavage. The control group was treated with corn oil by gavage. Perfusion of the livers occurred 24 
hours after treatment. Total RNA was isolated from cell pellets of HC and NPC. Finally DNA Chip analysis was 
performed with the Affymetrix Rat Genome 230 2.0 Array (Affymetrix).The data are means +/- SEM of three 
animals per treatment group. 
 
4.5.3 Influence of in vivo treatment with CPA on the expression of pro-inflammatory genes 
For a better analysis, pro-inflammatory genes were roughly separated in chemokines and 
cytokines, complement activators, activators of prostaglandin synthesis and genes involved 
in acute phase response (Figure 20). Table 12 lists the meanings of the abbreviated gene 
names. 
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Figure 20: Altered inflammatory response genes in HC and NPC due to CPA treatment in vivo. 
Female Wistar rats, 8-12 weeks old, were treated with a single dose of CPA (100 mg/kg body weight dissolved in 
corn oil) by gavage. The control group was treated with corn oil by gavage. Perfusion of the livers occurred 24 
hours after treatment. Total RNA was isolated from cell pellets of HC and NPC. Finally DNA Chip analysis was 
performed with the Affymetrix Rat Genome 230 2.0 Array (Affymetrix). The data are means +/- SEM of three 
animals per treatment group. 
 
Figure 20 demonstrates that there is a balance between upregulated and downregulated 
inflammatory factors in HC and NPC. In vivo treatment with CPA caused a downregulation of 
the chemokine Cxcl12 in both HC and NPC. The mRNA level of the pro-angiogenic gene 
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Cxcl1 was decreased by more than 50% in HC. Genes, which activate the complement 
system, such as Cfb, Cfh and Masp1 showed a significantly diminished expression level in 
HC. On the other side, the gene expression levels of six complement activating genes (Cfh, 
Fcnb, Masp2, Mbl2, C8a, C8b) were increased up to 3-fold in NPC. Three genes, which are 
involved in prostaglandin synthesis, were 2.5-fold downregulated in HC. Many acute phase 
response genes such as the C-reactive protein (CRP) were significantly elevated in NPC.  
 
Table 12: List of full gene titles of pro-inflammatory genes which show altered gene expression by 
treatment with CPA in vivo. 
 
Gene Symbol 
 
 
Gene Title 
 
Apoa2 apolipoprotein A-II 
C8a complement component 8, alpha polypeptide 
C8b complement component 8, beta polypeptide 
Ccl17 chemokine (C-C motif) ligand 17 
Ccl24 chemokine (C-C motif) ligand 24 
Ccl4 chemokine (C-C motif) ligand 4 
Ccl9 chemokine (C-C motif) ligand 9 
Cfb complement factor B 
Cfh complement factor H 
Crp C-reactive protein, pentraxin-related 
Cxcl1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
Cxcl10 chemokine (C-X-C motif) ligand 10 
Cxcl11 chemokine (C-X-C motif) ligand 11 
Cxcl12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 
Fcnb ficolin B 
Kng1 kininogen 1 /// kininogen 1-like 1 
Kng2 kininogen 2 
Masp1 mannan-binding lectin serine peptidase 1 
Masp2 mannan-binding lectin serine peptidase 2 
Mbl2 mannose-binding lectin (protein C) 2 
Mug1 murinoglobulin 1 
Nupr1 nuclear protein, transcriptional regulator, 1 
Orm1 orosomucoid 1 
Psme3 proteasome (prosome, macropain) activator subunit 3 
Ptger3 Prostaglandin E receptor 3 
Ptgis prostaglandin I2 (prostacyclin) synthase 
Ptgr1 prostaglandin reductase 1 
Saa4 serum amyloid A4, constitutive 
 
4.5.4 Influence of treatment with CPA on the ERK pathway 
Many studies established that altered gene transcription can be observed in the ERK 
pathway during the development of different types of cancers including HCC (see section 
1.4.4). The transcriptional analysis of the CPA short-term in vivo study came to a comparable 
result (Figure 21).  
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Figure 21: Scheme on ERK pathway components, deregulated in HC due to CPA treatment in vivo. 
Symbols: ↓ indicates ≥ 2-fold downregulated genes; ↑ indicates ≥ 2-fold upregulated genes; grey font indicates not 
regulated genes. 
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Figure 22: Effect of in vivo CPA treatment on the ERK pathway in HC. 
Female Wistar rats, 8-12 weeks old, were treated with a single dose of CPA (100 mg/kg body weight dissolved in 
corn oil) by gavage. The control group was treated with corn oil by gavage. Perfusion of the livers occurred 24 
hours after treatment. Total RNA was isolated from cell pellets of HC and NPC. Finally DNA Chip analysis was 
performed with the Affymetrix Rat Genome 230 2.0 Array (Affymetrix). The data are means +/- SEM of three 
animals per treatment group. 
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As illustrated by figure 21, most of the genes involved in the ERK pathway were altered in 
HC of rats which were treated in vivo with a single dosage of CPA. By contrast, in NPC no 
meaningful alterations in the ERK pathway could be found.  
 
The data (Figure 22) revealed a more than 2-fold upregulation of oncogenes, such as Ras 
and Raf or the apoptosis mediating gene Shc1. One of the possible start points of the 
pathway, namely EGFR and two of its ligands were deregulated. EGF resulted in a more 
than 3-fold downregulation and neuregulin 1 was 2-fold upregulated in HC. The key player 
ERK and its regulated gene Myc showed increased expression levels in HC.  
 
4.6 The MAPK/ERK pathway on protein level 
As short-term CPA in vivo study affecting many genes of the ERK pathway (see section 4.5), 
the protein level of phosphorylated (activated) ERK was examined in cultured HC and NPC 
which were treated with PB or CPA. The phosphorylation status of the ERK1 and ERK2 
proteins was checked from total protein lysates of untreated and treated primary liver cells by 
Western Blot analysis (see section 3.10.4). The antibodies recognize two distinct protein 
bands at 44 und 46 kDa representing the two ERK proteins. 
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4.6.1 Effect of PB treatment on ERK phosphorylation 
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Figure 23: Phosphorylation of ERK1/2 in HC and NPC treated with PB. 
The livers of male Wistar rats were perfused; cells were separated in HC and NPC and kept in culture. The cells 
were treated with PB (1 mM)  2 hours after seeding or stayed untreated as controls. The proteins were harvested 
10 min, 30 min, 1h, 3h and 24h after treatment. The proteins were separated via SDS-Page and transferred on a 
PVDF membrane. The target proteins ERK1/2 and pERK1/2 were detected with specific antibodies and visualized 
on X-ray films. A ß-actin antibody was used for protein integrity and equivalent loading. The signal intensities 
were evaluated by densitometry (Quantity One 4.2.1; Bio-Rad Laboratories, USA). At first, the signal intensities of 
pERK1/2 were normalized to the signal intensities of ERK1/2 (= fold ERK1/2). Finally the values of the treated 
cells were referred to the values of the untreated cells (= fold control). The data are means +/- SEM of two 
independent experiments. (A) CPA effect on ratio of pERK1/2 to total ERK1/2; (B) Representative Western Blots 
of ERK1/2, pERK1/2 and ß-actin. 
 
The degree of ERK phosphorylation in HC was highest when cells were treated 10 min with 
PB and slowly decreased over time whereas NPC showed a contrary phosphorylation 
pattern with the highest activity after 24 hours treatment (Figure 23A). 
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4.6.2 Effect of CPA treatment on ERK phosphorylation 
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Figure 24: Phosphorylation of ERK1/2 in NPC treated with CPA. 
The livers of female Wistar rats were perfused; cells were separated in NPC and kept in culture. The cells were 
treated with CPA (10 µM) or DMSO (0.2%) as control 2 hours after seeding. The proteins were harvested 10 min, 
30 min, 1h, 3h and 24h after treatment. The proteins were separated via SDS-Page and transferred on a PVDF 
membrane. The target proteins ERK1/2 and pERK1/2 were detected with specific antibodies and visualized on X-
ray films. A ß-actin antibody was used for protein integrity and equivalent loading. The signal intensities were 
evaluated by densitometry (Quantity One 4.2.1; Bio-Rad Laboratories, USA). At first, the signal intensities of 
pERK1/2 were normalized to the signal intensities of ERK1/2 (= fold ERK1/2). Finally the values of the treated 
cells were referred to the values of the DMSO treated cells (= fold control DMSO). The data are means +/- SEM 
of four independent experiments. (A) Effects of CPA on ratio of pERK1/2 on total ERK1/2; (B) Representative 
Western Blots of ERK1/2, pERK1/2 and ß-actin. 
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When NPC were treated with CPA, the degree of ERK phosphorylation showed similarity to 
treatment with PB as the peak with a 2-fold increase in phosphorylation activity was 
observed after 24 hours (Figure 24A). The other time points showed no significant change 
compared to the control levels. 
 
At all, these results indicate that PB may influence the activity of the ERK proteins in HC. The 
impact of the ERK pathway in tumor promotion requires further investigations. 
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5. Discussion 
NGC are a large group of chemicals that induce tumor formation by mechanisms which are 
different to direct DNA damage. (Mally, et al., 2002) As most of the studies concentrate on 
hepatocytes, the role of mesenchymal cells in carcinogenesis induced by NGC has found 
little attention so far. However, NGC have been shown to activate both HC and NPC, 
resulting in secretion of growth factors, pro-inflammatory cytokines and ROS. (Parzefall, et 
al., 2001) Besides, some of these growth factors have been found to be selective for 
preneoplastic liver lesions (PNL), serving as endogenous tumour promoters. Thus, HB-EGF 
secreted by NPC seems to be part of the growth stimulating circuit of rodent liver PNL. 
(Sagmeister, et al., 2008) Cooperation between NGC and the altered geno-/phenotype of 
preneoplasias may result in formation of stable autocrine loops in which growth factors, e.g. 
TGFα, stimulate their own synthesis and thereby induce steadily excessive growth. (Drucker, 
et al., 2006) This thesis aims to identify growth factors and chemo-/cytokines from primary 
liver cells especially mesenchymal cells, driving excessive responses of PNL towards NGC. 
This knowledge is essential to better understand the carcinogenic mode of action of the 
model NGC PB, CPA and WY. 
 
5.1.1 Are NPC direct targets of NGC effects? 
It is well known that many CYP candidates such as Cyp2b1 serve as markers indicating a 
response of primary liver cells to NGC. In this project, the in vitro and in vivo effect of NGC 
on CYP expression was tested separately for HC and NPC. 
 
In vitro effects of NGC on CYP expression 
We found very low basal expression levels of the examined CYP enzymes (Cyp1a1, Cyp2b1, 
Cyp2b2, Cyp2c12 and Cyp4a1) in untreated HC, EC and KC kept for 24 hours in culture. 
Treatment of HC with PB doubled gene expression of Cyp2b1 when compared to untreated 
controls. This result confirmed previous studies describing Cyp2b1 to be greatly induced by 
PB. Moreover, both PB and CPA were found as strong inducers of Cyp2c12 expression in 
HC and EC. In vitro treatment with CPA sharply increased Cyp1a1 expression in HC and KC 
whereas treatment with PB increased Cyp1a1 expression in EC. Thus, there is evidence that 
the mesenchyme show responses to NGC treatment. 
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In vivo effects of NGC on CYP expression 
The data obtained from the in vivo study differ from the in vitro results. Treatment of rats with 
a single dose of CPA for approximately 24 hours changed gene expression of a broad range 
of CYP members. The steroid hydroxylase Cyp17a1 plays an important role in androgen 
biosynthesis and was found to be downegulated by half in HC. This may also confirm the 
anti-androgenic effect of CPA. Additionally, Cyp2b1 expression may not just serve as a 
positive control for the PB effect but also for the CPA in vivo effect. We saw a 10-fold 
upregulation of Cyp2b1 in NPC and HC after in vivo treatment with CPA. To conclude, NPC 
may react towards NGC as shown by upregulated CYP in this cell compartment. 
 
5.1.2 Do NPC express NR? 
NR, like CAR and PXR, are able to regulate drug metabolism which includes the 
transcriptional regulation of CYP genes. Because of that, the basal NR expression and a 
possible induction of NR transcripts were investigated separately for HC and NPC in this 
study. 
 
Basal expression of NR in liver cell types 
We found, that untreated HC express many NR such as CAR, PXR and PPARα in a higher 
level than NPC do. However, KC and EC show also a cell specific expression pattern of the 
tested NR. 
 
In vitro effects of NGC on NR expression 
Treatment of primary liver cells with CPA reduced gene expression of the hormone receptor 
ERα by half in HC compared to the DMSO control. Additionally, CPA strongly reduced gene 
expression of PXR in EC. As expected, treatment of primary liver cells with the peroxisome 
proliferator WY slightly increased expression of PPARα in EC but surprisingly not in HC and 
KC. The exposure of primary liver cells to PB enhanced CAR expression in EC. At all, the 
obtained data allow the assumption that EC may contribute to the NR-mediated effect of 
NGC.  
 
Which NR is the primary target receptor for CPA? 
Additionally, we searched for the NR which carries out the effects of CPA. Therefore, specific 
inhibitors for PXR and CAR, in combination with CPA treatment, were applied. We tested the 
effects of the PXR inhibitor SFN and the CAR inhibitor PK-11195 on mRNA level and 
whether the inhibitors are able to block CPA induced DNA synthesis in HC.  
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On mRNA level, the inhibitor used for PXR (SFN) and CAR (PK-11195) failed to achieve any 
effect, as has been anticipated. However, the PXR inhibitor SFN was able to block the 
induction of DNA replication in HC. The CAR inhibitor PK-11195 had no effect. This might 
indicates that CPA seems to exert its effect on DNA replication of HC via PXR. Future 
experiments with CAR and PXR knock-out mice might be a good possibility for studying in 
detail the role of CAR and PXR in NGC-mediated carcinogenesis. 
 
In vivo effect of NGC on NR expression 
The short-term CPA in vivo study could not confirm the in vitro results. The expression of NR 
such as CAR and PXR stayed unchanged with CPA treatment compared to the oil control. It 
seems that a single application of CPA is not able to induce an effect on NR expression 
patterns of primary liver cells. 
 
5.1.3 What are the effects of in vivo treatment with CPA on the whole transcriptome? 
A solid way to get an overview about the mode of action of NGC on mRNA level is an in vivo 
experiment in combination with a Gene Chip analysis. We wanted to know whether in vivo 
application of a single dose of CPA (100 mg/kg body weight) changes the transcriptome in 
liver cells. The resulting expression levels were related to the expression levels of the control 
group (oil treated rats). 
 
To summarize, the larger part of altered genes was found in HC, i.e. more than 500 genes 
were found to be downregulated and more than 740 genes were in the upregulated state. In 
NPC, the in vivo exposure to CPA caused a downregulation of more than 90 genes and an 
upregulation of more than 450 genes. Many of these genes play important roles in 
inflammation, cell cycle, apoptosis, cell proliferation and detoxification. However, this data 
reflect again the problem that the in vivo and in vitro results differ in many aspects as shown 
by gene expression levels of different CYP and NR in the present study (see sections 4.1 
and 4.2). These discrepancies might be explained by many different factors such as the 
dedifferentiation of HC in culture caused by the loss of the 3-dimensional configuration of the 
cell, lack of cell-cell and cell-matrix contacts and the absence of epithelial-mesenchymal 
interactions. It is well known that P450 expression and activity rapidly decline in conventional 
HC monolayer cultures, resulting in the loss of responsiveness to some metabolic enzyme 
inducers, especially PB. (Su, et al., 2004) Co-culture systems or the use of liverbeads would 
be worth considering as they are closer to the in vivo situation. 
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Altered inflammatory factors 
It is well accepted that chronic inflammation plays a huge role in tumor promotion and that an 
inflammatory microenvironment is an essential feature of all tumors. (Grivennikov, et al., 
2010) Interestingly, only a single application of CPA caused deregulation of inflammatory 
genes involved in (1) chemo-/cytokine mediated response, (2) prostaglandin synthesis, (3) 
complement activation and (4) acute phase response. Many pro-inflammatory factors were 
downregulated in HC (12 downregulated genes vs. 2 upregulated genes) while the opposite 
was true for NPC (15 upregulated genes vs. 2 downregulated genes). This confirms again 
the strong reaction of the mesenchyme in response to in vivo treatment with CPA.  
 
It is mentionable that the chemokine Ccl9 was more than 2.5-fold upregulated in NPC due to 
CPA in vivo treatment. The chemokine Ccl9 is produced by cancer cells in order to recruit 
specific immune cells (CCR1+ myeloid cells) which in turn promote invasion of cancer cells 
through secretion of the matrix metalloproteinases MMP2 and MMP9. (Grivennikov, et al., 
2010) This alteration might contribute to the potent tumor promoting effects of CPA. 
 
5.1.4 Are their direct or indirect effects of NGC on NPC? 
The various cell types of the liver carry out their functions not in a solitary way but rather act 
as an integrated community in order to fulfil all the complex tasks of this organ. Therefore, we 
asked whether NGC act in a direct way on NPC or in an indirect way via factors released by 
HC. This might explain the strong response of NPC towards NGC. Although these cells 
barely express several important NR. Furthermore, HC may receive the NGC-mediated 
signal directly or indirectly via NPC.  
 
Interaction between HC and NPC 
In detail, we treated rats with PB for 24 hours or for two weeks. Afterwards, the cells were 
separated in HC and NPC and cultured. 24 hours later the supernatant of NPC, isolated from 
PB-treated rats, was collected in order to treat HC which were isolated from untreated rats 
and vice versa. Supernatant derived from HC and NPC, which had been isolated from 
untreated rats, served as controls. The gene expression levels of the pro-inflammatory 
mediators TNFα, IL-6, COX-2 and iNOS were studied in order to determine whether the 
supernatant acts in a pro- or in an anti-inflammatory way. 
 
The supernatants of NPC, obtained from untreated rats, led to a strong overexpression of 
TNFα, COX-2, iNOS and IL-6 in HC. This was even more pronounced when the supernatant 
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derived from NPC isolated from PB-treated animals. Surprisingly, when NPC were treated 
with the secretome of HC, obtained from untreated rats, the expression of the genes studied 
was significantly lowered which indicates an anti-inflammatory effect of HC on NPC. 
Interestingly, PB-treated HC had an even stronger anti-inflammatory impact on the 
mesenchymal cells than control HC.  
 
In conclusion, NPC might react on the PB treatment by secretion of pro-inflammatory factors 
which lead to an inflammatory signature in HC. It appears possible that a prolonged 
exposure to NGC would then lead to a chronic low-level inflammation which in return could 
be the starting point for the development of liver cancer. 
 
Direct and indirect effects of NGC 
As already discussed, the weak response of NPC to treatment with CPA, PB or WY in vitro 
may be caused by dedifferentiation of the cells in culture or by cell separation which disrupts 
HC and NPC as interacting partners. Moreover, the supernatant studies showed a strong 
interaction between the parenchymal and mesenchymal cells. This may be mediated by 
different pro-inflammatory factors such as cytokines. The analysis of the secretome of HC 
and NPC, derived from PB treated rats, via TNFα ELISA failed to identify TNFα as possible 
factor, as the measured concentrations were very low. As a consequence, the search for the 
soluble factors which lead to the strong response in HC and NPC has to be extended in the 
future.   
 
5.1.5 Which pathway is affected by NGC? 
It is common knowledge that the ERK pathway regulates the cell cycle progression via 
different transcription factors. (Schmitz, et al., 2008) A marked change within this signalling 
cascade has fatal consequences such as enhanced cell proliferation, which might lead to 
cancer. (Goodsell, 1999) 
 
In vivo effects of CPA on ERK pathway 
We found that the application of a single dose of CPA leads to an altered expression of many 
genes involved in the ERK pathway of HC. The proto-oncogenes Ras and Raf are related to 
control cell growth and differentiation and were found to be more than 2-fold upregulated. 
The EGF is mitogenic for HC through the binding to its receptor EGFR. A relation between 
the overexpression of the EGFR pathway and the development of HCC has often been 
described. (Schiffer, et al., 2005) Thus, it is intriguing that we found a more than 50% 
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reduction in gene expression of EGFR and EGF due to CPA treatment in vivo. This may 
indicate a counter-regulation following a stimulation of EGFR-mediated signalling. 
Furthermore, a chronic administration of NGC might have had a completely different effect 
on the various EGF-receptors and its ligands.  
 
In vitro effects of NGC on ERK activity 
Phosphorylation of ERK proteins leads to cellular and/or nuclear responses dependent on 
the stimulus, the ERK isoform activated (ERK1 or ERK2) and the cell type studied. (McKillop, 
et al., 2003) We wanted to know whether treatment with different NGC changes the activity 
of ERK proteins. Therefore, we determined the degree of phosphorylation of ERK1/2 in 
response to in vitro treatment with PB and CPA via specific antibodies and Western Blot 
analysis. For a better monitoring of the ERK activity, different treatment time points were 
used. 
 
HC which were treated for 10 min with PB showed the highest activity of ERK. Additionally, 
the phosphorylation grade decreased with increasing treatment time. In NPC, activity of ERK 
increased up to 2-fold after 24 hours treatment with PB. Short treatment (10 min – 3 hours) of 
NPC with CPA slightly decreased ERK phosphorylation but after 24 hours phosphorylation 
increased up to 2-fold. However, late phosphorylation probably indicates a result with less 
significance. 
 
The results confirmed that the activity of the ERK proteins is cell type specific and plays a 
role in the mode of action of NGC. A higher ERK activity over a long time period might lead 
to altered cell growth in primary liver cells and in further consequence might contribute to the 
development of HCC. However, the involvement of the ERK pathway in tumor promotion 
needs further investigation. 
 
5.1.6 Conclusion and perspectives 
Research in NGC-related hepatocarcinogenesis has been reaching big milestones in the last 
few years. However, there are still many open questions such as the identification of the key 
factors which promote tumor development and progression. The relationship between 
inflammation and HCC will be a good basis for further experiments. The overall aim for future 
studies will be the identification of possible biomarkers in order to prevent the development of 
liver cancer driven by NGC.   
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6. Abstract 
As particularly aggressive cancer entity, hepatocellular carcinoma (HCC) causes about half a 
million deaths per year. Therefore, it is important to eliminate putative cancer risk factors and 
to understand the mechanisms underlying the pathogenesis of this tumor. Many drugs 
prescribed to millions of people worldwide belong to the class of non-genotoxic 
hepatocarcinogens (NGC), i.e. they do not feature genotoxicity but produce tumors in long-
term rodent bioassays. The significance of these findings for human liver cancer risk is not 
clear. This thesis aimed to study the mode of action of prototypical NGC (phenobarbital, PB; 
cyproterone acetate, CPA; and Wyeth, WY) in order to better estimate whether NGC may 
pose a risk to human health. Hitherto, research has been focusing on hepatocytes (HC) as 
direct target cells of NGC. Since there is evidence that NGC are able to act also on non-
parenchymal liver cells (NPC), the present study was designed to investigate the effects of 
NGC, separately for HC and NPC. 
 
As main experimental approaches, rats were treated with PB or CPA either once or for a 
prolonged period of time. The cells were isolated from rat liver by collagenase perfusion, 
were separated into HC and NPC by percoll gradient centrifugation, were seeded to culture 
plates and were treated with PB, CPA, or WY for up to 24 hours. Analysis of altered gene 
expression patterns was performed via conventional polymerase chain reaction (PCR), 
quantitative Real-Time PCR (qrt-PCR) as well as by Gene Chip analysis of the whole 
transcriptome. Furthermore, the phosphorylation of extracellular signal-regulated kinase 
(ERK1/2) proteins was analysed in HC and NPC exposed to PB and CPA in vitro. The impact 
of the secretome of untreated or PB treated NPC on the pro-inflammatory state of HC was 
investigated. The same was done with NPC exposed to supernatants derived from untreated 
or PB treated HC. Changes in mRNA level of pro-inflammatory genes, such as the tumor 
necrosis factor-alpha (TNFα) or interleukin-6 (IL-6), served as end point. 
   
HC were found to express considerably the nuclear receptors (NR) PXR and PPARα and to 
lower extent CAR and ERα. Compared to HC, the expression levels of NR in EC and KC 
were lower or even negligible. In primary culture, HC are able to respond to NGC as 
indicated by elevated mRNAs of cytochrome P450 enzymes (Cyp1a1, Cyp2b1 and Cyp2c12) 
while the effect on mesenchymal cells was partially weaker. This was similar with the 
phosphorylation of ERK1/2 proteins in PB-treated cultured HC. Furthermore, Gene Chip 
analysis revealed the upregulation of components of the ERK pathway in HC exposed to 
CPA in vivo. As a consequence, NGC action may involve this signalling pathway.  
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With regard to epithelial-mesenchymal interactions, the secretome from untreated NPC 
triggered a pro-inflammatory response in HC which was aggravated when NPC had been 
exposed to PB in vivo. In contrast, supernatants of untreated HC suppressed transcription 
levels of pro-inflammatory genes in NPC which became more pronounced when supernatant 
of PB-exposed HC was applied. The results indicate a profound epithelial-mesenchymal 
dialogue for the fine tuning of expression levels in liver cell types and that NGC may interfere 
with these interactions.  
 
In summary, the present work could gain evidence that NGC may promote 
hepatocarcinogenesis by affecting signalling pathways and altering the pro-inflammatory 
state in both, mesenchymal and parenchymal liver cells. 
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7. Zusammenfassung 
Das hepatozelluläre Karzinom (HCC), als besonders aggressiver Tumor, führt zu über einer 
halben Million Todesfälle pro Jahr. Es ist daher von Bedeutung, die potentiellen 
Risikofaktoren auszuschalten und die Entstehung dieser Krankheit besser zu verstehen. 
Viele, an Millionen von Menschen weltweit, verschriebene Medikamente zählen zu der 
Gruppe von nicht gentoxischen Kanzerogenen (NGC), das heißt sie sind nicht gentoxisch, 
erzeugen aber Tumore in Ratten in Langzeit „Bioassays“. Die Bedeutung dieser Ergebnisse 
für den humanen Leberkrebs ist nicht eindeutig. Das Ziel dieser Diplomarbeit war die 
Erforschung der Wirkungsweise von prototypischen NGC (Phenobarbital, PB; Cyproterone 
Acetat, CPA und Wyeth, WY), um das Risiko für die Gesundheit des Menschen besser 
einschätzen zu können. Bislang lag der Schwerpunkt der Forschung auf Hepatozyten (HC) 
als direkte Zielzellen von NGC. Da es Hinweise gibt, dass NGC auch auf nicht parenchymale 
Zellen der Leber (NPC) wirken, wurden die Experimente in der Weise aufgebaut, dass die 
Effekte von NGC gesondert für HC und NPC untersucht werden konnten. 
 
Die Versuche basierten darauf, dass die Ratten entweder einmalig oder für einen längeren 
Zeitraum mit PB oder CPA behandelt wurden. Die Zellen wurden mittels Kollagenase 
Perfusion aus der Rattenleber isoliert, mittels Percoll Gradienten Zentrifugation in HC und 
NPC aufgetrennt, auf Kulturplatten ausgesät und mit PB, CPA, oder WY für bis zu 24 
Stunden behandelt. Die Analyse von veränderten Genexpressionsmustern erfolgte mit Hilfe 
der Polymerase-Ketten-Reaktion (PCR), quantitativer Real-Time PCR (qrt-PCR), sowie DNA 
Chip Analyse des gesamten Transkriptoms. Des Weiteren wurde die Phosphorylierung der 
„extracellular-signal regulated kinase“ (ERK1/2) Proteine untersucht, die in vitro mit PB oder 
CPA behandelt worden waren. Die Auswirkung der Zellüberstände von unbehandelten oder 
PB behandelten NPC auf den pro-entzündlichen Status von HC wurde erforscht. Das 
Gleiche wurde mit NPC, welche den Zellüberständen von unbehandelten oder PB 
behandelten HC ausgesetzt wurden, durchgeführt. Die Veränderung der mRNA Level von 
pro-entzündlichen Genen, wie zum Beispiel des Tumornekrosefaktors (TNFα) oder 
Interleukin-6 (IL-6), diente als Endpunkt. 
 
Es stellte sich heraus, dass HC hauptsächlich die Nuklearen Rezeptoren (NR) PXR und 
PPARα und im geringeren Ausmaß CAR und ERα exprimieren. Im Vergleich zu HC waren 
die Expressionslevel der NR in Endothelzellen und Kupfferzellen geringer oder sogar 
vernachlässigbar. Es zeigte sich, dass HC in Primärkulturen in der Lage sind auf NGC in 
Form von erhöhter mRNA der Zytochrom-P450 Isoenzyme (Cyp1a1, Cyp2b1 und Cyp2c12) 
  
 
77 
 
zu reagieren, wohingegen der Effekt von NGC auf mesenchymale Zellen teilweise geringer 
ausfiel. Das Gleiche galt für die Phosphorylierung der ERK1/2 Proteine in PB behandelten 
HC. Zusätzlich ergab die Gene Chip Analyse von HC, welche aus CPA behandelten Tieren 
isoliert worden waren, eine Hochregulierung von Genen des ERK Signalweges. 
Infolgedessen könnte dieser Signalweg bei der Wirkungsweise von NGC eine Rolle spielen. 
 
In Bezug auf die epithelialen-mesenchymalen Wechselwirkungen löste das Sekretom aus 
unbehandelten NPC eine pro-entzündliche Reaktion in HC aus. Diese wurde verschärft, 
wenn NPC eingesetzt wurden, die aus PB behandelten Tieren stammten. Im Gegensatz 
dazu führten die Überstände aus unbehandelten HC zu einer Unterdrückung der 
Transkriptionslevel von pro-entzündlichen Genen in NPC. Dieser Effekt wurde durch den 
Einsatz von Überständen aus PB behandelten HC noch verstärkt. Die Ergebnisse deuten auf 
einen fundierten epithelialen-mesenchymalen Dialog hin, welcher zur Feinabstimmung der 
Expressionslevel in Leberzelltypen dienen könnte. Es wäre denkbar, dass NGC in diese 
Interaktionen eingreifen. 
 
Zusammenfassend erlangte diese Arbeit Hinweise darauf, dass NGC möglicherweise die 
Leberkrebsentstehung durch Beeinflussung von Signalwegen und Veränderungen des pro-
entzündlichen Status in mesenchymalen und parenchymalen Leberzellen fördern könnte. 
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